10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 001-41358

ACLARION, INC.

(Exact name of registrant as specified in its charter)

Delaware	47-3324725
(State or other jurisdiction of incorporation)	(IRS Employer Identification No.)

8181 Arista Place, Suite 100

Broomfield, Colorado 80021

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (833) 275-2266

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.00001 per share	ACON	The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of Common stock	ACONW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒

As of August 25, 2023, there were 8,200,875 shares of the registrant's common stock, $0.00001 par value per share, outstanding.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Forward-looking statements are subject to risks and uncertainties that could cause actual results to be materially different from those indicated (both favorably and unfavorably). These risks and uncertainties include, but are not limited to, those described in the Risk Factors section of the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2022 (the Form 10-K/A) dated June 12, 2023, as filed with the Securities and Exchange Commission on June 12, 2023, under Rule 424(b)(4). Caution should be taken not to place undue reliance on any such forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward- looking statements in this Quarterly Report on Form 10-Q by these cautionary statements.

2

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements	4
	Condensed Balance Sheets	4
	Condensed Statements of Operations	5
	Condensed Statements of Changes in Stockholders' Equity (Deficit)	6
	Condensed Statements of Cash Flows	8
	Notes to Condensed Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	31
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3.	Defaults Upon Senior Securities	32
Item 4.	Mine Safety Disclosures	32
Item 5.	Other Information	32
Item 6.	Exhibits	33
	Signatures	35

3

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Aclarion, Inc.

Condensed Balance Sheets

	Jun 30, 2023			Dec 31, 2022
	(Unaudited)			(restated)
ASSETS
Current assets:
Cash	$	604,518		$	1,472,806
Restricted cash		10,000			10,000
Accounts receivable		10,365			18,569
Prepaids and other current assets		173,204			199,701
Total current assets		798,087			1,701,076
Non-current assets:
Property and equipment, net		2,342			3,346
Intangible assets, net		1,204,037			1,210,207
Total non-current assets		1,206,378			1,213,553
Total assets	$	2,004,466		$	2,914,629
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	607,616		$	462,202
Accrued and other liabilities		513,000			226,469
Note payable, net of discount		118,838			–
Warrant liability		582,399			–
Derivative liability		172,389			–
Total current liabilities		1,994,242			688,671
Stockholders' equity
Common stock - $0.00001 par value, 200,000,000 authorized and 8,200,875 and 7,861,515 shares issued and outstanding (see Note 12)		82			79
Additional paid-in capital		42,028,310			41,596,032
Accumulated deficit		(42,018,169	)		(39,370,153	)
Total stockholders’ equity (deficit)		10,223			2,225,958
Total liabilities and stockholders’ equity (deficit)	$	2,004,466		$	2,914,629

See accompanying notes to condensed financial statements.

4

Aclarion, Inc.

Condensed Statements of Operations

(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
				(restated)						(restated)
Revenue
Revenue	$	17,072		$	10,676		$	42,542		$	19,702
Cost of revenue		19,301			14,249			36,754			30,981
Gross profit (loss)		(2,229	)		(3,573	)		5,788			(11,279	)
Operating expenses:
Sales and marketing		207,790			124,759			385,074			194,067
Research and development		250,006			353,226			454,405			558,029
General and administrative		946,175			1,731,190			1,753,774			2,222,473
Total operating expenses		1,403,971			2,209,175			2,593,253			2,974,569
(Loss) from operations		(1,406,200	)		(2,212,748	)		(2,587,465	)		(2,985,848	)
Other (expense):
Interest expense		(47,139	)		(1,340,666	)		(48,519	)		(1,503,407	)
Change in value of warrant and derivative liabilities		(11,800	)		–			(11,800	)		–
Other, net		583			(1,447	)		(234	)		(1,695	)
Total other (expense)		(58,356	)		(1,342,114	)		(60,552	)		(1,505,102	)
(Loss) before income taxes		(1,464,557	)		(3,554,862	)		(2,648,017	)		(4,490,950	)
Income tax provision		–			–			–			–
Net (loss)	$	(1,464,557	)	$	(3,554,862	)	$	(2,648,017	)	$	(4,490,950	)
Dividends accrued for preferred stockholders		–			(128,208	)		–			(415,523	)
Net (loss) allocable to common stockholders	$	(1,464,557	)	$	(3,683,070	)	$	(2,648,017	)	$	(4,906,473	)
Net (loss) per share allocable to common shareholders	$	(0.18	)	$	(0.47	)	$	(0.33	)	$	(1.12	)
Weighted average shares of common stock outstanding, basic and diluted		8,287,669			7,821,515			8,119,982			4,373,668

See accompanying notes to condensed financial statements.

5

Aclarion, Inc.

Condensed Statements of Changes in Stockholders' Equity (Deficit)

(unaudited)

Series A

Series A-1, A-2, A-3, A-4

Series B, B-1

Series B-2, B-3

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Shares

Value

Shares

Value

Shares

Value

Shares

Value*

Balance, December 31, 2021

–

$

–

6,247,695

$

62

12,434,500

$

124

5,812,809

$

–

Preferred stock dividend payable

–

–

–

–

–

–

–

–

Share-based compensation

–

–

–

–

–

–

–

–

Net income (loss)

–

–

–

–

–

–

–

–

Balance, March 31, 2022

–

$

–

6,247,695

$

62

12,434,500

$

124

5,812,809

$

–

Issuance of warrants

–

–

–

–

–

–

–

–

Exercise of convertible note warrants

–

–

–

–

–

–

–

–

Preferred stock dividend payable

–

–

–

–

–

–

–

–

Conversion of preferred dividends payable to common stock

–

–

–

–

–

–

–

–

Conversion of preferred stock to common stock

–

–

(6,247,695

)

(62

)

(12,434,500

)

(124

)

(5,812,809

)

–

Conversion of accrued interest on promissory notes

–

–

–

–

–

–

–

–

Issuance of common stock and warrants related to IPO, net issuance costs

–

–

–

–

–

–

–

–

IPO issuance costs

–

–

–

–

–

–

–

–

Share-based compensation

–

–

–

–

–

–

–

–

Net income (loss)

–

–

–

–

–

–

–

–

Balance, June 30, 2022

–

$

–

–

$

–

–

$

–

–

$

–

Balance, December 31, 2022

–

$

–

–

$

–

–

$

–

–

$

–

Share-based compensation

–

–

–

–

–

–

–

–

Proceeds from sale of Series A preferred stock

1

1,000

–

–

–

–

–

–

Redemption of Series A Preferred stock

(1

)

(1,000

)

–

–

–

–

–

–

Net income (loss)

–

–

–

–

–

–

–

–

Balance, March 31, 2023

–

$

–

–

$

–

–

$

–

–

$

–

Share-based compensation

–

–

–

–

–

–

–

–

Issuance of common shares

–

–

–

–

–

–

–

–

Issuance of warrants

–

–

–

–

–

–

–

–

Net income (loss)

–

–

–

–

–

–

–

–

Balance, June 30, 2023

–

$

–

–

$

–

–

$

–

–

$

–

* Series B2 and B3 Preferred Stock amounts reflected in mezzanine equity in the relevant reporting periods.

(continued)

6

Aclarion, Inc.

Condensed Statements of Changes in Stockholders' Equity (Deficit)

(unaudited)

(continued)

	Common Stock			Additional			Accumulated
	Shares	Value		Paid-In Capital			Deficit			Total
Balance, December 31, 2021	905,685	$	9	$	19,054,234		$	(31,886,036	)	$	(12,831,606	)
Preferred stock dividend payable	–		–		–			(287,315	)		(287,315	)
Share-based compensation	–		–		23,122			–			23,122
Net income (loss)	–		–		–			(936,088	)		(936,088	)
Balance, March 31, 2022	905,685	$	9	$	19,077,356		$	(33,109,439	)	$	(14,031,887	)
Issuance of warrants	–		–		1,280			–			1,280
Exercise of convertible note warrants	60,408		1		(1	)		–			–
Preferred stock dividend payable	–		–		–			(128,208	)		(128,208	)
Conversion of preferred dividends payable to common stock	984,537		10		4,272,411			–			4,272,420
Conversion of preferred stock to common stock	3,279,117		33		7,102,441			–			7,102,287
Conversion of accrued interest on promissory notes	426,768		4		1,855,154			–			1,855,158
Issuance of common stock and warrants related to IPO, net issuance costs	2,165,000		22		8,552,318			–			8,552,340
IPO issuance costs	–		–		(530,463	)		–			(530,463	)
Share-based compensation	–		–		701,505			–			701,505
Net income (loss)	–		–		–			(3,554,862	)		(3,554,862	)
Balance, June 30, 2022 (restated)	7,821,515	$	78	$	41,032,001		$	(36,792,509	)	$	4,239,570
Balance, December 31, 2022	7,861,515	$	79	$	41,596,032		$	(39,370,153	)	$	2,225,958
Share-based compensation	–		–		82,531			–			82,531
Proceeds from sale of Series A preferred stock	–		–		–			–			1,000
Redemption of Series A Preferred stock	–		–		–			–			(1,000	)
Net income (loss)	–		–		–			(1,183,460	)		(1,183,460	)
Balance, March 31, 2023	7,861,515	$	79	$	41,678,563		$	(40,553,613	)	$	1,125,029
Share-based compensation	–		–		136,631			–			136,631
Issuance of common shares	339,360		3		175,616			–			175,619
Issuance of warrants	–		–		37,500			–			37,500
Net income (loss)	–		–		–			(1,454,557	)		(1,464,557	)
Balance, June 30, 2023	8,200,875	$	82	$	42,028,310		$	(42,018,169	)	$	10,223

See accompanying notes to condensed financial statements.

7

Aclarion, Inc.

Condensed Statements of Cash Flows

(unaudited)

	Six Months Ended June 30,
	2023			2022
				(restated)
Cash flows from operating activities
Net (loss)	$	(2,648,017	)	$	(4,490,950	)
Adjustments to reconcile net (loss) to net cash used in operation activities:
Depreciation and amortization		79,809			69,705
Share-based compensation		219,162			724,627
Amortization of deferred issuance costs		28,520			–
Change in fair value of warrants and derivative		11,800			–
Non-cash interest related to bridge funding		14,346			–
Loss on disposal of furniture and equipment		–			1,886
Interest conversion discount settled in equity		–			1,299,508
Change in assets and liabilities
Accounts receivable		1,414			1,243
Prepaids and other current assets		33,287			(448,434	)
Accounts payable		57,914			119,072
Accrued and other liabilities		241,110			(193,320	)
Accrued interest on promissory and convertible notes		–			200,712
Net cash (used in) operations		(1,960,653	)		(2,715,951	)
Cash flows from investing activities
Intangible assets - Patents		(72,634	)		(121,957	)
Proceeds from sale of furniture		–			1,000
Net cash (used in) investing activities		(72,634	)		(120,957	)
Cash flows from financing activities
Proceeds from bridge funding		1,250,000			–
IPO/bridge funding issuance costs		(85,000	)		(365,060	)
Repayment of promissory notes		–			(2,000,000	)
Issuance of common stock and warrants related to IPO, net deductions		–			8,552,318
Proceeds from sale of Series A preferred stock		1,000			–
Redemption of Series A Preferred stock		(1,000	)		–
Net cash provided by financing activities		1,165,000			6,187,258
Net cash increase (decrease) for period		(868,287	)		3,350,350
Cash and restricted cash, beginning of period		1,482,806			452,530
Cash and restricted cash, end of period	$	614,518		$	3,802,880
Non- cash activities
Dividends accrued on preferred shares	$	–		$	415,523
Conversion of preferred stock to common stock	$	–		$	25,754,379
Conversion of preferred stock dividends to common stock	$	–		$	4,272,421
Conversion of accrued interest on promissory notes to common stock and warrants	$	–		$	1,856,438
Issuance of underwriter's warrants related to IPO	$	–		$	199,246
Designation of prepaid expenses to IPO issuance costs	$	–		$	165,403
Fair value of warrants and derivative related to bridge funding	$	742,988		$	–
Issuance of commitment shares related to bridge funding	$	175,619		$	–
Accrued debt issuance costs related to bridge funding	$	118,575			–
Issuance of warrants related to bridge funding	$	37,500		$	–
Original issuance discount (15%) related to bridge funding	$	187,500			–

See accompanying notes to condensed financial statements.

8

Aclarion, Inc.

Notes to Condensed Financial Statements

(unaudited)

NOTE 1. THE COMPANY AND BASIS OF PRESENTATION

The Company

Aclarion, Inc., formerly Nocimed, Inc., (the “Company”, “we”, or “Aclarion”) is a healthcare technology company that leverages magnetic resonance spectroscopy (“MRS”), and a proprietary biomarker to optimize clinical treatments. The Company was formed in February 2015, is incorporated in Delaware, and has its principal place of business in Broomfield, Colorado.

Basis of Presentation

The accompanying condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information required by U.S. GAAP for complete financial statements. The interim condensed financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair representation of the results for the periods presented and should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2022, which include a complete set of footnote disclosures, including our significant accounting policies. The December 31, 2022 condensed balance sheet was derived from the December 31, 2022 audited financial statements. They should be read in conjunction with the financial statements and notes thereto included in our Annual report on Form 10-K/A, filed with the SEC on June 12, 2023. The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Risks and Uncertainties

The Company is subject to various risks and uncertainties frequently encountered by companies in the early stages of development. Such risks and uncertainties include, but are not limited to, its limited operating history, competition from other companies, limited access to additional funds, dependence on key personnel, and management of potential rapid growth. To address these risks, the Company must, among other things, develop its customer base; implement and successfully execute its business and marketing strategy; develop follow-on products; provide superior customer service; and attract, retain, and motivate qualified personnel. There can be no guarantee that the Company will be successful in addressing these or other such risks.

On March 3, 2023, we received a letter from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. At December 31, 2022, we reported stockholders’ equity of $1,787,751 (prior to restatement, see Note 4 of form 10-K/A filed June 12, 2023), and, as a result, we did not satisfy Listing Rule 5550(b)(1). Nasdaq allowed us a period of 45 calendar days from the date of the letter, or until April 17, 2023, to submit a plan to regain compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). We submitted such a plan to Nasdaq on April 12, 2023. On April 20, 2023, the Company received a letter from Nasdaq granting us an additional 180-day period, or until August 30, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Separately, on August 4, 2023, we received a notice from Nasdaq indicating that we were not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). This notice indicated that the Company will be provided 180 calendar days in which to regain compliance. If at any time during this 180 calendar day period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq staff (the “Staff”) will provide the Company with a written confirmation of compliance and the matter will be closed.

Alternatively, if the Company fails to regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, the Company may be eligible for an additional 180 calendar day compliance period, provided (i) it meets the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the Bid Price Requirement) and (ii) it provides written notice to Nasdaq of its intention to cure this deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event the Company does not regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, and if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is not otherwise eligible, the Staff will provide the Company with written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Company intends to consider all options to regain compliance with all Nasdaq continued listing requirements.

9

Initial Public Offering

On April 26, 2022, the Company completed its initial public offering (“IPO”) of 2,165,000 units, at a public offering price of $4.35 per unit. Each unit consisted of (i) one share of common stock and (ii) one common stock warrant with an exercise price of $4.35 per share. Following the commencement of the IPO, the underwriters partially exercised their over-allotment option and purchased an additional 324,750 common stock warrants. After deducting underwriter's commissions and expenses, the Company received net proceeds of approximately $8.6 million, and our common stock and warrants started trading on Nasdaq under the ticker symbols “ACON” and “ACONW”, respectively.

Concurrently with the IPO, holders of the Company’s promissory notes, along with accrued interest, and preferred stock, along with accrued dividends, and certain outstanding common stock warrants were converted into 4,750,830 shares of the Company’s common stock and 426,768 common stock warrants.

In connection with the IPO, we issued to the representative of the underwriters a common stock warrant for 173,200 shares with an exercise price of $5.44 per share. The representative's warrants were exercisable commencing October 26, 2022, and will expire on April 26, 2027.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The financial statements include some amounts that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and valuation of warrants and options to purchase shares of the Company's common stock. These estimates may be adjusted as more current information becomes available, and any adjustment could be significant.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1 - Unadjusted quoted prices in active markets for identical instruments that are accessible by the Company on the measurement date.

Level 2 - Quoted prices in markets that are not active or inputs which are either directly or indirectly observable.

Level 3 - Unobservable inputs for the instrument requiring the development of assumptions by the Company.

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The carrying values of the Company’s financial instruments including cash equivalents, restricted cash, accounts receivable, and accounts payable are approximately equal to their respective fair values due to the relatively short-term nature of these instruments. The Company’s warrant liabilities and derivative liabilities are estimated using level 3 inputs (see Note 3).

10

Derivative Financial Instruments

The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expenses), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at June 30, 2023 and December 31, 2022. The Company maintains cash deposits at several financial institutions, which are insured by the FDIC up to $250,000. The Company’s cash balance may at times exceed these limits. On June 30, 2023, and December 31, 2022, the Company had $81,088 and $1,229,863, respectively, in excess of federally insured limits. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company maintains no international bank accounts. As of June 30, 2023, the Company reported cash of $604,518 and restricted cash of $10,000 which aggregates to $614,518 and is reported on the statement of cash flows as cash and restricted cash.

Accounts Receivable, Less Allowance for Doubtful Accounts

The Company estimates an allowance for doubtful accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was $0 on June 30, 2023, and December 31, 2022.

Revenue Recognition

Revenues are recognized when a contract with a customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report, the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees. To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the billing schedules in its sales arrangements. Payment terms range generally from prepayment to 90 days from the date of invoice.

Liquidity, Capital Resources and Going Concern

The Company had a cash and restricted cash balance of $614,518 as of June 30, 2023. On May 16, 2023, we entered into a securities purchase agreement with accredited investors for unsecured non-convertible note financing. The Company received $1,250,000 of gross proceeds in connection with the first tranche closing of this financing. The Company has the option, subject to certain conditions, to close on a second tranche of this financing. If the second tranche is closed, the Company will receive an additional $750,000 of gross proceeds. This interim bridge funding should allow the Company to operate into the third quarter of 2023. Management is actively managing our cash position and working to secure longer-term funding.

As a result of the Company’s recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.

Share-Based Compensation

The Company issues stock-based compensation awards to employees and directors in the form of stock options. The Company measures and recognizes compensation expense for all stock-based awards based on the awards’ fair value. Share-based compensation for stock options awards is measured on the date of grant using a Black-Scholes-Merton option pricing model.

Awards vest either on a graded schedule or at the grant date. The Company determines the fair value of each award as a single award and recognizes the expense on a straight-line basis over the service period of the award, which is generally the vesting period. The exercise price of stock options granted is equal to the fair market value of the Company’s common stock on the date of grant. Stock options expire ten years from the date of grant.

11

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period to comply with certain new or revised accounting standards that have different effective dates for public and private companies.

NOTE 3. FAIR VALUE MEASUREMENTS

In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the outstanding warrants, certain embedded redemption features associated with the senior note to Aclarion, Inc. on a recurring basis to determine the fair value of the liability.

	Fair value measured as of June 30, 2023
	Fair value on June 30, 2023		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Warrant liability	$	582,399	$	–	$	–	$	582,399
Derivative Liability		172,389		–		–		172,389
Total Fair value	$	754,788	$	–	$	–	$	754,788

There were no transfers between Level 1, 2, and 3 during the period ended June 30, 2023, and the year ended December 31, 2022.

The following table presents changes in Level 3 liabilities measures at fair value for the period ended June 30, 2023, and the year ended December 31, 2022. Both observable and unobservable inputs were used to determine the fair value positions that the Company has classified within the Level 3 category. 

	Warrant Liability		Derivative Liability		Total
Balance - January 1, 2023	$	–	$	–	$	–
Additional warrant and derivative liability		579,818		163,170		742,988
Change in fair value		2,581		9,219		11,800
Balance - June 30, 2023	$	582,399	$	172,389	$	754,788

The fair value of the embedded derivative liabilities associated with the Senior Notes Payable was estimated using a probability weighted discounted cash flow model to measure the fair value. This involves significant Level 3 inputs and assumptions including an (i) estimated probability and timing of certain financing events and event of default, and (ii) the Company’s risk-adjusted discount rate.

The fair value of the warrants to purchase shares of common stock was estimated using a Monte Carlo simulation using the following assumptions. 

	As of Issuance		As of June 30, 2023
	Warrant Liability		Warrant Liability
Strike Price	$	0.63	$	0.63
Contractual term (years)		5.0		5.0
Volatility (annual)		80.0%		80.0%
Risk-free rate		3.52%		4.15%
Floor Financing price	$	0.50	$	0.50

12

NOTE 4. RECENT ACCOUNTING PRONOUNCEMENTS

In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”), which simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. The guidance also modifies how certain convertible instruments, that may be settled in cash or shares, impact the calculation of diluted earnings per share. ASU 2020-06 allows for a modified or full retrospective method of transition. This update is effective for emerging growth companies following private company adoption dates in fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company adopted this standard as of April 1, 2022, using the modified retrospective approach. The adoption of this guidance did not have a material impact on the accompanying unaudited condensed consolidated financial statements.

On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as amended, which replaces the incurred loss methodology with an expected loss methodology, that is referred to as a current expected loss methodology (CECL). CECL was required to be implemented for small business reporting companies after December 31, 2022. The measurement of expected losses under the CECL methodology is applicable to financial assets measured at amortized cost, including trade receivables, loan receivables and held-to-maturity debt securities. It also applies to off balance sheet credit exposures not accounted for as insurance, loan commitments, standby letters of credit, financial guarantees, and similar instruments and net investment in leases, as accounted for by the lessor under ASC 842. In addition, ASC 326 made changes to the available for-sale debt securities. One such change is to require credit losses be accounted for as an allowance instead of a write-down on available for-sale securities that management does not intend to sell, or believes it is more likely than not that they will be required to sell.

The Company has adopted ASC 326 using the retrospective approach for all financial assets measured at amortized cost, which consists of trade receivables. The Company estimates the likelihood of collection considering trade receivables-based factors such as the creditworthiness of its customers. There are no off-balance sheet assets or guarantees. The Company recorded no change to retained earnings due to the adoption of ASC 326.

As of this date, the Company has not purchased, nor does it intend to purchase, debt securities, eroded or financial assets, or leases within the scope of the pronouncement. If it does, it will use the prospective transition approach.

NOTE 5. REVENUE

Contract Balances

The timing of revenue recognition, billings, and cash collections may result in trade, unbilled receivables, and deferred revenues on the balance sheets. At times, revenue recognition may occur before the billing, resulting in an unbilled receivable, which would represent a contract asset. The contract asset would be a component of accounts receivable and other assets for the current and non-current portions, respectively. A contract liability is recorded when the Company receives payments prior to earning the revenue.

13

NOTE 6. CORRECTION OF ERRORS IN 2022 INTERIM FINANCIAL INFORMATION

Subsequent to the initial issuance of the Company's 2022 financial statements on February 27, 2023, management discovered that the previously issued interim financial statements for the three and six months ended June 30, 2022 and the nine months ended September 30, 2022 did not properly record the following items in accordance with US GAAP:

(a)	the statement of cash flows inaccurately presented costs associated with the Initial Public Offering in the operating section, instead of the financing section and
(b)	a charge of $152,653 for the exercise of warrants at the time of the Initial Public Offering was incorrectly recorded as expense.

Additionally, management introduced various reclassifications within the statement of cash flows to present in accordance with US GAAP. The following tables summarize the impacts of these error corrections on the Company's interim financial statements for each of the interim periods presented below:

Condensed Balance Sheets	For the six months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Total assets	$	5,620,989		$	–		$	5,620,989
Total current liabilities		1,381,419			–			1,381,419
Additional paid-in capital		41,184,654			(152,653	)		41,032,001
Accumulated deficit		(36,945,162	)		152,653			(36,792,509	)
Other		78			–			78
Total stockholders’ equity		4,239,570			–			4,239,570
Total liabilities and stockholders’ equity	$	5,620,989		$	–		$	5,620,989

Condensed Statements of Operations	For the six months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Gross profit (loss)	$	(11,279	)	$	–		$	(11,279	)
Sales and marketing		194,067			–			194,067
Research and development		558,029			–			558,029
General and administrative		2,375,126			(152,653	)		2,222,473
Total operating expenses		3,127,222			(152,653	)		2,974,569
Total other income (expense)		(1,505,102	)		–			(1,505,102	)
Net income (loss)	$	(4,643,603	)	$	152,653		$	(4,490,950	)
Net (loss) allocable to common stockholders	$	(5,059,126	)	$	152,653		$	(4,906,473	)
(Loss) per share	$	(1.16	)	$	0.04		$	(1.12	)
Weighted Average common shares outstanding		4,363,600			10,068			4,373,668

14

Condensed Statements of Operations	For the three months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Gross profit (loss)	$	(3,573	)	$	–		$	(3,573	)
Sales and marketing		124,759			–			124,759
Research and development		353,226			–			353,226
General and administrative		1,883,843			(152,653	)		1,731,190
Total operating expenses		2,361,828			(152,653	)		2,209,175
Total other income (expense)		(1,342,114	)		–			(1,342,114	)
Net income (loss)	$	(3,707,515	)	$	152,653		$	(3,554,862	)
Net (loss) allocable to common stockholders	$	(3,835,723	)	$	152,653		$	(3,683,070	)
(Loss) per share	$	(0.49	)	$	0.02		$	(0.47	)
Weighted Average common shares outstanding		7,821,515			–			7,821,515

Condensed Statements of Cash Flows	For the six months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Net income (loss)	$	(4,643,603	)	$	152,653		$	(4,490,950	)
Adjustments to reconcile net income (loss) to net cash used in operation activities
Depreciation and amortization		94,705			(25,000	)		69,705
Non-cash charge settled in equity		–			1,299,507			1,299,507
Prepaids and other current assets		(308,052	)		(140,382	)		(448,434	)
Accrued and other liabilities		728,399			(921,718	)		(193,320	)
Other		1,047,540			–			1,047,540
Net cash (used in) operations		(3,081,011	)		365,060			(2,715,951	)
Net cash (used in) investing activities		(120,957	)		–			(120,957	)
IPO Issuance costs		–			(365,060	)		(365,060	)
Others		6,552,318			–			6,552,318
Net cash provided by financing activities		6,552,318			(365,060	)		6,187,258
Net cash increase (decrease) for period	$	3,350,350		$	–		$	3,350,350

Condensed Statements of Changes in Stockholders’ Equity	June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Common Stock	$	78		$	–		$	78
Additional paid-in capital		41,184,654			(152,653	)		41,032,001
Accumulated deficit		(36,945,162	)		152,653			(36,792,509	)
Total stockholders’ equity	$	4,239,570		$	–		$	4,239,570

15

NOTE 7. SUPPLEMENTAL FINANCIAL INFORMATION

Balance Sheets

Accrued and other liabilities: 

	June 30, 2023		December 31, 2022
Accrued bonus	$	291,812	$	134,704
Accrued expenses		153,805		35,922
Accrued payroll and related liabilities		47,023		46,250
Accrued interest		14,346		–
Other accrued liabilities		6,014		9,593
	$	513,000	$	226,469

NOTE 8. LEASES

Rent expense for the three months ended June 30, 2023, and 2022, was $0 and $16,425, respectively. Rent expense for the six months ended June 30, 2023, and 2022, was $0 and $32,510, respectively.

The Company entered into a subleasing agreement in 2021 and realized $0 and $26,340 of sublease income for the six months ended June 30, 2023, and 2022. Both the lease and sublease are netted within the general & administrative line item in the Condensed Statements of Operations. Our current office lease and sublease expired on June 30, 2022.

NOTE 9. INTANGIBLE ASSETS

The Company’s intangible assets are as follows: 

	June 30, 2023			December 31, 2022
Patents and licenses	$	2,220,363		$	2,147,728
Other		5,017			5,017
		2,225,380			2,152,745
Less: accumulated amortization		(1,021,343	)		(942,538	)
Intangible assets, net	$	1,204,037		$	1,210,207

Patents and licenses costs are accounted for as intangible assets and amortized over the life of the patent or license agreement and charged to research and development.

Amortization expense related to purchased intangible assets was $39,940 and $33,396 for the three months ended June 30, 2023, and 2022, respectively. Amortization expense related to purchased intangible assets was $78,805 and $66,583 for the six months ended June 30, 2023, and 2022, respectively.

Patents and trademarks are reviewed at least annually for impairment. No impairment was recorded through June 30, 2023, and December 31, 2022, respectively.

Future amortization of intangible assets is as follows: 

2023	$	81,096
2024		162,191
2025		162,191
2026		162,191
2027 and beyond		636,368
Total	$	1,204,037

16

NOTE  10. SHORT TERM NOTES, CONVERTIBLE DEBT, AND DERIVATIVE LIABILITIES

Senior Notes Payable

In May 2023, the Company issued $1,437,500 unsecured senior notes that mature on May 16, 2024 (“the Senior Notes Payable”), for cash proceeds of $1,250,000. The Senior Notes Payable contain an original issue discount of 15.0% and accrue interest at an annual rate of 8.0%. The Company incurred issuance costs, recorded as deferred financing costs, of $203,575 relating to due diligence and legal costs associated with the transaction.

The Company evaluated the embedded redemption and contingent interest features in the Senior Notes Payable to determine if such features were required to be bifurcated as an embedded derivative liability. In accordance with ASC 815-40, Derivatives and Hedging Activities, the embedded redemption features and contingent interest feature were accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value at each reporting date. The Company fair valued such derivative liabilities and recorded a debt discount at issuance of $163,170.

The Company issued warrants to purchase 1,232,156 shares of common stock to the holders (the “Senior Notes Warrants”) with an exercise price of $0.6262 per share. The Company accounted for the warrants in accordance with the guidance contained in ASC 815 “Derivatives and Hedging” whereby under that provision these warrants did not meet the criteria for equity treatment and were recorded as a liability. As such, these warrants are recorded at fair value as of each reporting date with the change in fair value reported within other income in the accompanying consolidated statements of operations as “Change in fair value of warrant liability” until the warrants are exercised, expired or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity. The fair value of the Senior Notes Warrants at issuance was $579,818 and was recorded as a debt discount.

In connection with the issuance of the Senior Notes Payable, the Company paid a commitment fee in the form of 339,360 shares of unregistered common stock to the holders. The commitment fee has a fair value at issuance of $175,619 and is recorded as a deferred financing cost.

The resulting debt discounts from the derivative liabilities, warrant liabilities and deferred financing costs were presented as a direct deduction from the carrying amount of that debt liability and amortized to interest expense using the effective interest rate method. For the six months ended June 30, 2023, the Company recognized $28,520 in amortization of debt discounts and deferred financing costs which is recorded in interest expense.

The following table reconciles the Senior Notes Payable and unamortized deferred financing costs and debt discounts relating to the derivative liabilities and warrant liabilities.

Note payable, net of discount: 

	June 30, 2023			December 31, 2022
Note Payable	$	1,437,500		$	–
Less: Unamortized Discounts and Deferred Financing Costs					–
Warrants		(567,543	)		–
Derivative		(159,716	)		–
Issuance cost		(591,403	)		–
		(1,318,662	)		–
	$	118,838		$	–

Promissory Notes Payable

In June 2021, the Company issued $2.0 million of promissory notes that matured at the earlier of the consummation of a Qualified Financing or May 31, 2022. The promissory notes incorporated the following major attributes: secured by a lien and security interest on substantially all of the Company’s assets; interest accrues at 33%; holder option to convert the accrued interest into the Company securities being offered in a Qualified Financing at 30% (i.e. 70% discount) of the price being paid by other investors in the Qualified Financing; and automatic conversion in the case of a Qualifying IPO of the accrued interest into the Company securities being offered in the Qualifying IPO at 30% (70% discount) of the price being paid by other investors in the Qualifying IPO. If the promissory notes remained outstanding after May 31, 2022, the Company had the option to extend the promissory notes upon the payment of an extension fee, which consisted of 150,000 warrants (20,080 warrants post-split) with a five-year term, to purchase shares of the Company’s common stock at a price of $ 0.01 per share ($0.0747 post-split).

On April 21, 2022, the registration statement for our IPO was declared effective. In connection with the effectiveness of the IPO registration statement, all accrued interest on the Company's outstanding secured promissory notes was converted into (i) 426,768 post-split common shares and (ii) 426,768 post-split common stock warrants, with a $1,299,507 beneficial conversion rate charged to interest expense.

On April 27, 2022, the Company used $2 million of the IPO proceeds to retire all outstanding secured promissory notes.

17

NOTE 11. COMMITMENTS AND CONTINGENCIES

Royalty Agreement

The Company has an exclusive license agreement with the Regents of the University of California to make, use, sell and otherwise distribute products under certain of the Regents of the University of California’s patents anywhere in the world. The Company is obligated to pay a minimum annual royalty of $50,000, and an earned royalty of 4% of net sales. The minimum annual royalty will be applied against the earned royalty due for the calendar year in which the minimum payment was made. The license agreements expire upon expiration of the patents and may be terminated earlier if the Company so elects. The U.S. licensed patents that are currently issued expire between 2026 and 2029, without considering any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. The Company recorded royalty costs of $12,500 for the three months ended June 30, 2023, and 2022, respectively, and $25,000 for the six months ended June 30, 2023, and 2022, respectively, as Cost of Revenue.

Litigation

To date, the Company has not been involved in legal proceedings arising in the ordinary course of its business. If any legal proceeding occurs, the Company will record a provision for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated, although litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position and cash flows.

NOTE 12. STOCKHOLDERS’ EQUITY

The Company filed an Amended and Restated Certificate of Incorporation on April 21, 2022, as part of the IPO. The Company is authorized to issue two classes of stock to be designated, respectively, “common stock” and “preferred stock.” The total number of shares which the Company is authorized to issue is two hundred twenty million (220,000,000) shares. Two hundred million (200,000,000) shares are authorized to be common stock, having a par value per share of $0.00001. Twenty million (20,000,000) shares are authorized to be preferred stock, having a par value per share of $0.00001. As of June 30, 2023, the Company had 8,200,875 common shares outstanding.

Stockholders’ Vote – Reverse stock split

We held a special meeting of stockholders on March 24, 2023. At the special meeting, our stockholders approved one proposal, which was to grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-five (1-for-5) to a maximum of a one-for-fifty (1-for-50) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal was approved by stockholders.

Series A-1, A-2, A-3, A-4, B, B-1, B-2, and B-3 Preferred Stock

Prior to the IPO, the Company had authorized two classes of shares. These classes included shares of common stock and preferred stock. There was one authorized series of shares of common stock and eight existing authorized series of preferred stock: Series A-1, A-2, A-3, A-4, B, B-1, B-2, and B-3.

The Series B, B-1, B-2 and B-3 preferred stock earned a dividend rate is 6.0%. Dividends were cumulative. The accrued and unpaid dividends were payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock.

The preferred shares converted to common shares on a 1:1 pre-split basis immediately prior to the Stock Split on April 21, 2022.

18

Series A Preferred Stock

In February 2023 the Company sold one (1) share of the Company’s newly designated Series A preferred stock to Jeffrey Thramann, the Company’s Executive Chairman, for a purchase price of $1,000. The share of Series A preferred stock had proportional voting rights that were limited to the proposal to approve a reverse stock split of the Company’s common stock. Following the March 24, 2023, special meeting, the Company redeemed the one outstanding share of Series A preferred stock on March 28, 2023, in accordance with its terms. The redemption price was $1,000. No Series A preferred stock remains outstanding.

Warrants

Pre-Funded Placement Agent Warrants

During the six months ended June 30, 2023, the Company issued 54,340 shares of common stock in the form of pre-funded warrants to the placement agent in connection with the Senior Notes Payable issuance discussed in Note 10. The value of the warrants was recorded as a debt discount on the Notes.

Warrants issued with Convertible Notes

During the years ended December 31, 2022, and 2021, the Company issued 17,286 and 58,846 warrants, respectively, to certain investors who participated over an agreed investment minimum amount in the purchase of our convertible notes. The value of the warrants was recorded as a debt discount and expensed based on the fair value. Just prior to the IPO, these common stock warrants were exercised on a net share basis for 60,408 common shares (451,245 pre-split shares).

Warrants issued in connection with the IPO

In connection with the Company’s IPO, all accrued interest on the Company's outstanding secured promissory notes were converted into (i) 426,768 post-split common shares and (ii) 426,768 post-split common stock warrants, with beneficial conversion rates charged to interest expense upon conversion. These warrants have an exercise price of $4.35 per share.

In the IPO, the Company sold 2,165,000 units, at a public offering price of $4.35 per unit. Each unit consisted of (i) one share of common stock and (ii) one common stock warrant (“IPO Warrant”) with an exercise price of $4.35 per share. The common stock and the IPO Warrants were immediately separable and issued separately in the offering. The IPO Warrants are listed and tradeable on the NASDAQ stock market, immediately exercisable at the option of the holder, and expire five years from the date of issuance.

On April 22, 2022, the IPO underwriters partially exercised their over-allotment option for an additional 324,750 IPO Warrants.

In connection with the IPO, we issued to the representative of the underwriters common stock warrants for 173,200 shares with an exercise price of $5.44 per share. The representative's warrants are exercisable commencing October 26, 2022, and will expire on April 26, 2027.

The Company evaluated the terms of all warrants issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging. Since the Company determined that the warrants were equity classified, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance of proceeds to additional paid in capital.

As of June 30, 2023, 2,489,750 IPO Warrants were outstanding.

19

NOTE 13. NET LOSS PER SHARE OF COMMON STOCK

Basic and diluted net loss per share is computed by dividing net loss attributable to stockholders by the weighted average number shares of common stock outstanding during the period and shares issuable for vested restricted stock units. Potentially dilutive outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to stockholders follows:  

	Three Months Ended June 30,
	2023			2022
Numerator:
Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share	$	(1,464,557	)	$	(3,683,070	)
Denominator:
Weighted average shares outstanding used to compute basic and dilutive loss per share		8,087,755			–
Weighted average shares issuable for vested restricted stock units		199,914			–
		8,287,669			7,821,515

	Six Months Ended June 30,
	2023			2022
Numerator:
Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share	$	(2,648,017	)	$	(4,906,473	)
Denominator:
Weighted average shares outstanding used to compute basic and dilutive loss per share		7,974,635			4,373,668
Weighted average shares issuable for vested restricted stock units		145,347			–
		8,119,982			4,373,668

20

The following outstanding potentially dilutive securities were excluded from the weighted average calculation of dilutive loss per share attributable to common stockholders because their impact would have been antidilutive for the period presented: 

	June 30, 2023		June 30, 2022
Series A and B convertible preferred stock		–		1,639,559
Warrants		3,518,550		1,570,236
Restricted stock units		692,422		–
Stock options		2,738,820		2,351,510
		6,949,792		5,561,305

NOTE 14. STOCK BASED COMPENSATION

2022 Aclarion Equity Incentive Plan

On April 21, 2022, in connection with the IPO, the Company adopted the 2022 Aclarion Equity Incentive Plan, or “2022 Plan”. Our board of directors has appointed the compensation committee of our board of directors as the committee under the 2022 Plan with the authority to administer the 2022 Plan. The initial aggregate number of our shares of common stock that may be issued under the 2022 Plan was 2,000,000 shares, subject to adjustments as described in the 2022 Plan.

The 2022 Plan contains an “evergreen” provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased on the first day of each year beginning in 2023 equal to the lesser of (a) five percent (5%) of the shares of stock outstanding on the last day of the immediately preceding fiscal year and (b) such smaller number of shares of stock as determined by our board of directors. On January 1, 2023, an additional 393,076 shares were added to the 2022 Plan pursuant to the evergreen provision. As a result, the aggregate number of our shares of common stock that may be issued under the 2022 Plan has been increased to 2,393,076 shares.

Options granted under the 2022 Plan may be incentive stock options or non-statutory stock options, as determined by the administrator at the time of grant of an option. RSUs and restricted stock may also be granted under the 2022 Plan. Grants vest in accordance with the grant terms. Options generally are exercisable for a period of up to 10 years from the grant date.

No options were granted in the three months and six months ended June 30, 2023.

Nocimed, Inc. 2015 Stock Plan

The Company maintains the Nocimed, Inc. 2015 Stock Plan, or the “Existing Plan”, under which the Company could grant 2,440,931 post-split shares or options of the Company to our employees, consultants, and other service providers. The Company suspended the Existing Plan in connection with the IPO. No further awards will be granted under the Existing Plan, but awards granted prior to the IPO will continue in accordance with their terms and the terms of the Existing Plan.

Determining Fair Value of Stock Options

The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

Valuation and Amortization Method —The Company estimates the fair value of its stock options using the Black-Scholes-Merton option-pricing model. This fair value is then amortized over the requisite service periods of the awards.

Expected Term—The Company estimates the expected term of stock option by taking the average of the vesting term and the contractual term of the option, as illustrated by the simplified method.

Expected Volatility—The expected volatility is derived from the Company’s expectations of future market volatility over the expected term of the options.

Risk-Free Interest Rate—The risk-free interest rate is based on the 10-year U.S. Treasury yield curve on the date of grant.

Dividend Yield—The dividend yield assumption is based on the Company’s history and expectation of no dividend payouts.

21

Stock Award Activity

A summary of option activity under the Company’s incentive plans is as follows:

	Options Outstanding		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)		Aggregate Intrinsic Value of Unexercised Options
Balance at December 31, 2022		2,738,820	$	1.94		8.4	$	0
Options granted		–		–		–
Options exercised		–		–		–
Options forfeited/expired		–		–		–
Balance at June 30, 2023		2,738,820	$	1.94		7.9	$	0
Exercisable at December 31, 2022		2,169,088	$	1.87		8.3	$	0
Exercisable at June 30, 2023		2,283,224	$	1.89		7.8	$	0

The aggregate intrinsic value in the table above of the unexercised options reflects the total pre-tax intrinsic value (the difference between the Nasdaq closing price on June 30, 2023, and the exercise price of the options that would have been received by option holders if all options exercisable had been exercised).

As of June 30, 2023, there was approximately $443,251 of total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over the next 27 months.

Restricted Stock Units

In the six months ended June 30, 2023, the Company granted RSUs under the 2022 Plan that have a combination of time-based and performance-based vesting, contingent upon continued service with the Company. The Company granted certain consultants an aggregate of 398,452 RSUs.

RSU activity under the 2022 Plan was as follows for the six months ended June 30, 2023: 

	RSU’s Outstanding			Weighted-Average Grant-Date Fair value per Unit
Nonvested as of December 31, 2022		446,525		$	0.63
Granted		398,452			0.76
Vested		(206,302	)		0.65
Forfeited		–			–
Nonvested as of June 30, 2023		638,675		$	0.70

22

The grant date fair value for a RSU is the market price of the common stock on the date of grant. The total share-based compensation expense related to RSUs recognized during the six months ended June 30, 2023, was $105,478.

As of June 30, 2023, there was approximately $281,330 total unrecognized compensation cost related to non-vested RSUs which is expected to be recognized over the next twelve months.

As of June 30, 2023, the Company is obligated to issue 241,692 shares of common stock associated with vested Restricted Stock Units.

Stock-based Compensation Expense

The following table summarizes the total stock-based compensation expense included in the Company’s statements of operations for the periods presented: 

	Three months ended June 30,				Six months ended June 30,
	2023		2022		2023		2022
Sales and marketing	$	78,688	$	848	$	106,997	$	1,696
Research and development		2,055		3,064		5,615		6,129
General and administrative		55,888		697,593		106,551		716,802
Total share based compensation	$	136,631	$	701,505	$	219,162	$	724,627

NOTE 15. SUBSEQUENT EVENTS

Resolution of Nasdaq Notice Regarding Late Filing of 10-Q Report

As previously disclosed, on May 23, 2023, the Company received a notice from Nasdaq notifying the Company that because the Company was delinquent in filing its Form 10-Q for the quarter ended March 31, 2023, the Company no longer complied with Nasdaq Listing Rule 5250(c)(1), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. On July 3, 2023, the Company filed its Form 10-Q for the quarter ended March 31, 2023 with the SEC. On July 5, 2023, the Company received a letter from Nasdaq indicating that the Company was now in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq’s letter indicated that this matter is now closed.

Nasdaq Non-Compliance

As indicated in our Form 12b-25 Notification of Late Filing filed on August 14, 2023, we have been delayed in filing with the SEC our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. On August 23, 2023, the Company received a notice from Nasdaq notifying the Company that because the Company remains delinquent in filing its Form 10-Q, the Company no longer complies with Nasdaq Listing Rule 5250(c)(1), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The notice received from Nasdaq has no immediate effect on the listing or trading of the Company’s securities on Nasdaq. However, if the Company would fail to timely regain compliance with Rule 5250(c)(1), the Company’s securities would be subject to delisting from Nasdaq. Under the Nasdaq rules, the Company has until October 22, 2023 (60 days after Nasdaq’s notice) to submit a plan to regain compliance with the Rule 5250(c)(1).  The Company expects that with the filing of this Form 10-Q, we have regained compliance with Rule 5250(c)(1).

23

Nasdaq Delisting Notices

On March 3, 2023, we received a letter from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. At December 31, 2022, we reported stockholders’ equity of $1,787,751 (prior to restatement, see Note 4 of form 10-K/A filed June 12, 2023), and, as a result, we did not satisfy Listing Rule 5550(b)(1). Nasdaq allowed us a period of 45 calendar days from the date of the letter, or until April 17, 2023, to submit a plan to regain compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). We submitted such a plan to Nasdaq on April 12, 2023. On April 20, 2023, the Company received a letter from Nasdaq granting us an additional 180-day period, or until August 30, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Separately, on August 4, 2023, we received a notice from Nasdaq indicating that we were not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). This notice indicated that the Company will be provided 180 calendar days in which to regain compliance. If at any time during this 180 calendar day period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq staff (the “Staff”) will provide the Company with a written confirmation of compliance and the matter will be closed.

Alternatively, if the Company fails to regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, the Company may be eligible for an additional 180 calendar day compliance period, provided (i) it meets the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the Bid Price Requirement) and (ii) it provides written notice to Nasdaq of its intention to cure this deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event the Company does not regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, and if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is not otherwise eligible, the Staff will provide the Company with written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Company intends to consider all options to regain compliance with all Nasdaq continued listing requirements.

Amendment to Unsecured Non-Convertible Notes

On May 16, 2023, the Company entered into a securities purchase agreement with accredited investors for an unsecured non-convertible note financing. The Company has received $1,250,000 of gross proceeds in connection with the first tranche closing of this financing.

Pursuant to the securities purchase agreement, the Company has the option, subject to certain conditions, to close on a second tranche of this financing. If the second tranche is closed, the Company would receive an additional $750,000 of gross proceeds in connection with the second tranche closing of this financing. The option for the second tranche is exercisable by the Company at any time until the earlier of (x) the date no first tranche notes remain outstanding and (y) the six-month anniversary of the first tranche closing date.

On August 14, 2023, the Company and the note holders agreed to waive monthly interest payments on the first tranche notes and the second tranche notes (if issued in the future).

24

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with the unaudited condensed financial statements and related notes included elsewhere in this Quarterly Report and our audited financial statements and related notes included in our Annual Report on Form 10-K/A for the year ended December 31, 2022, which was filed with the SEC on June 12, 2023. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Part II, Item 1A, “Risk Factors” and elsewhere in this Quarterly Report. You should carefully read the “Risk Factors” section of this Quarterly Report and of our Annual Report on Form 10-K/A for the year ended December 31, 2022, which was as filed with the SEC on June 12, 2023, to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled “Special Note Regarding Forward-Looking Statements.”

Overview

Corporate Information

We currently operate as a Delaware corporation, under the name Aclarion, Inc.

Results of operations

For the Three Months Ended June 30, 2023, and 2022:

The following table summarizes our results of operations for the three months ended June 30, 2023, and 2022.

	Three Months Ended June 30,
	2023			2022			$ Change
Revenue
Revenue	$	17,072		$	10,676		$	6,396
Cost of revenue		19,301			14,249			5,052
Gross profit (loss)		(2,229	)		(3,573	)		1,354
Operating expenses:
Sales and marketing		207,790			124,759			83,031
Research and development		250,006			353,226			(103,220	)
General and administrative		946,175			1,731,190			(785,014	)
Total operating expenses		1,403,971			2,209,175			(805,203	)
Income (loss) from operations		(1,406,200	)		(2,212,748	)		806,547
Other income (expense):
Interest expense		(47,139	)		(1,340,666	)		1,293,527
Changes in value of warrant and derivative liabilities		(11,800	)		–			(11,800	)
Other, net		583			(1,447	)		2,030
Total other income (expense)		(58,356	)		(1,342,114	)		1,283,758
Income (loss) before income taxes		(1,464,557	)		(3,554,862	)		2,090,305
Income tax provision		–			–			–
Net income (loss)	$	(1,464,557	)	$	(3,554,862	)	$	2,090,305
Dividends accrued for preferred stockholders	$	–		$	(128,208	)	$	128,208
Net income (loss) allocable to common stockholders	$	(1,464,557	)	$	(3,683,070	)	$	2,218,513
Net income (loss) per share allocable to common shareholders	$	(0.18	)	$	(0.47	)	$	0.29
Weighted average shares of common stock outstanding, basic and diluted		8,287,669			7,821,515			466,154

25

Total revenues. Total revenues for the quarter ended June 30, 2023 were $17,072, which was an increase of $6,396, or 60%, from $10,676 for the quarter ended June 30, 2022. The increase in revenues resulted from a Purchase Order from the University of North Carolina at Chapel Hill.

Cost of Revenue. Direct cost of revenue is comprised of hosting and software costs, field support, UCSF royalty cost, NuVasive commission of 6%, partner fees (Radnet), and credit card fees. Total cost of revenue was $19,301 for the quarter ended June 30, 2023, compared to $14,249 for the quarter ended June 30, 2022, an increase of 35%. This change is due to the increase in revenues and related costs.

Sales and Marketing. Sales and marketing expenses were $207,790 for the quarter ended June 30, 2023, compared to $124,759 for the quarter ended June 30, 2022, an increase of $83,031 or 67%. This increase was driven by Key Opinion Leader restricted stock unit vesting, conferences, and travel expenses.

Research and Development. Research and development expenses were $250,006 for the quarter ended June 30, 2023, compared to $353,266 for the quarter ended June 30, 2022, a decrease of $103,220 or 29%. The decrease was primarily driven by a $123,828 payment to UCSF for the quarter ended June 30, 2022 for a milestone license payment upon IPO.

General and Administrative. General and administrative expenses were $946,175 for the quarter ended June 30, 2023, a decrease of $785,014 or 45%, from $1,731,190 for the quarter ended June 30, 2022. The Company transitioned from private to public with its IPO in April 2022. For the quarter ended June 30, 2022, the Company incurred post-IPO expenses related to bonus payouts and stock compensation expenses, which were not incurred for the quarter ended June 30, 2023.

Interest Expense. Interest expense was $47,139 for the quarter ended June 30, 2023, a decrease of $1,293,527, from the $1,340,666 for the quarter ended June 30, 2022. The decrease in interest expense year-over-year was primarily driven by the $1.3 million beneficial conversion rate charged to interest expense for the conversion of all accrued interest on the Company's outstanding secured promissory notes into common shares and common stock warrants in connection with the effectiveness of the April 2022 IPO.

For the Six Months Ended June 30, 2023, and 2022:

The following table summarizes our results of operations for the six months ended June 30, 2023, and 2022.

	Six Months Ended June 30,
	2023			2022			$ Change
Revenue
Revenue	$	42,542		$	19,702		$	22,840
Cost of revenue		36,754			30,981			5,773
Gross profit (loss)		5,788			(11,279	)		17,067
Operating expenses:
Sales and marketing		385,074			194,067			191,006
Research and development		454,405			558,029			(103,624	)
General and administrative		1,753,774			2,222,473			(468,699	)
Total operating expenses		2,593,253			2,974,569			(381,316	)
Income (loss) from operations		(2,587,464	)		(2,985,848	)		398,384
Other income (expense):
Interest expense		(48,519	)		(1,503,407	)		1,454,888
Changes in value of warrant and derivative liabilities		(11,800	)		–			(11,800	)
Other, net		(234	)		(1,695	)		1,462
Total other income (expense)		(60,552	)		(1,505,102	)		1,444,550
Income (loss) before income taxes		(2,648,017	)		(4,490,950	)		1,842,934
Income tax provision		–			–			–
Net income (loss)	$	(2,648,017	)	$	(4,490,950	)	$	1,842,934
Dividends accrued for preferred stockholders	$	–		$	(415,523	)	$	415,523
Net income (loss) allocable to common stockholders	$	(2,648,017	)	$	(4,906,473	)	$	2,258,457
Net income (loss) per share allocable to common shareholders	$	(0.33	)	$	(1.12	)	$	0.79
Weighted average shares of common stock outstanding, basic and diluted		8,119,982			4,373,668			3,746,314

26

Total revenues. Total revenues for the six months ended June 30, 2023 were $42,542, which was an increase of $22,840, or 116%, from $19,702 for the six months ended June 30, 2022. The increase in revenues resulted from a Purchase Order from the University of North Carolina at Chapel Hill.

Cost of Revenue. Direct cost of revenue is comprised of hosting and software costs, field support, UCSF royalty cost, NuVasive commission of 6%, partner fees (Radnet), and credit card fees. Total cost of revenue was $36,754 for the six months ended June 30, 2023, compared to $30,981 for the six months ended June 30, 2022, an increase of 19%. This change is due to the increase in revenues and related costs.

Sales and Marketing. Sales and marketing expenses were $385,074 for the six months ended June 30, 2023, compared to $194,067 for the six months ended June 30, 2022, an increase of $191,006 or 98%. This increase was driven by Key Opinion Leader restricted stock unit vesting, conferences, and travel expenses.

Research and Development. Research and development expenses were $454,405 for the six months ended June 30, 2023, compared to $558,029 for the six months ended June 30, 2022, a decrease of $103,624. The decrease was primarily driven by a $123,828 payment to UCSF for the quarter ended June 30, 2022 related to a milestone license payment upon the April 2022 IPO.

General and Administrative. General and administrative expenses were $1,753,774 for the six months ended June 30, 2023, a decrease of $468,699 or 21%, from $2,222,473 for the six months ended June 30, 2022.

The Company transitioned from private to public with its IPO in April 2022. For the six months ended June 30, 2022, the Company incurred post-IPO expenses related to bonus payouts and stock compensation expenses, which were not incurred for the six months ended June 30, 2023. This year-over-year decrease in 2023 was partially offset by increased director and officer insurance premiums with six months paid in 2023 compared to just over two months in 2022.

Interest Expense. Interest expense was $48,519 for the six months ended June 30, 2023, a decrease of $1,454,888, from the $1,503,407 for the six months ended June 30, 2022. The decrease in interest expense year-over-year was primarily driven by the $1.3 million beneficial conversion rate charged to interest expense for the conversion of all accrued interest on the Company's outstanding secured promissory notes into common shares and common stock warrants in connection with the effectiveness of the April 2022 IPO.

Critical accounting policies and use of estimates

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates.

While our significant accounting policies are described in more detail in the notes to our financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.

Revenue Recognition

The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Revenues are recognized when a contract with a customer exists, and the control of the promised services are transferred to our customers. The amount of revenue recognized reflects the consideration we expect to receive in exchange for those services. Substantially all of our revenues are generated from contracts with customers in the United States.

27

Equity-Based Compensation

Certain of our employees and consultants have received grants of common stock options and RSUs in our company. These awards are accounted for in accordance with guidance prescribed for accounting for equity-based compensation. Based on this guidance and the terms of the awards, the awards are equity classified.

Until our April 2022 IPO, we were a private company with no active public market for our common equity. Therefore, we had periodically determined the overall value of our company and the estimated per share fair value of our common equity at their various dates using contemporaneous valuations performed in accordance with the guidance outlined in the American Institute of CPA’s Practice Aid. Since a public trading market for our common stock has been established in connection with the completion of our IPO, it will no longer be necessary for us to estimate the fair value of our common stock in connection with our accounting for equity awards we may grant, as the fair value of our common stock will be its public market trading price.

For financial reporting purposes, we performed common stock valuations as a private company with the assistance of a third-party specialist. Subsequent to the initial public offering, the fair value of the Company’s common stock underlying its equity awards is based on the quoted market price of the Company’s common stock on the grant date.

Going Concern

As a result of the Company’s recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.

The Company had a cash and restricted cash balance of $614,518 as of June 30, 2023. On May 16, 2023, we entered into a securities purchase agreement with accredited investors for unsecured non-convertible note financing. The Company received $1,250,000 of gross proceeds in connection with the first tranche closing of this financing. The Company has the option, subject to certain conditions, to close on a second tranche of this financing. If the second tranche is closed, the Company will receive an additional $750,000 of gross proceeds. This interim bridge funding should allow the Company to operate for approximately three months, into the third quarter of 2023. Management is actively managing our cash position and working to secure longer-term funding.

Liquidity and capital resources

Sources of liquidity

To date, we have financed our operations primarily through private placements of preferred shares and debt financing, PPP loans that were forgiven, and our IPO on April 21, 2022.

Through June 30, 2023, we raised an aggregate of $31,145,148 of gross proceeds from $19,319,098 of preferred and common stock, $2,928,541 from the sale of convertible notes, $370,191 of PPP loans that were forgiven, and net proceeds of $8,527,318 from the IPO, after underwriter compensation and deductions. We also issued a $2,000,000 promissory note in June 2021 that was repaid in April 2022. On May 16, 2023, the Company entered into a securities purchase agreement with accredited investors for an unsecured non-convertible note financing. The Company received $1,250,000 of gross proceeds, with out-of-pocket issuance costs of $203,575. As of June 30, 2023, we had cash, including $10,000 of restricted cash, of $614,518.

On May 16, 2023, the Company entered into a securities purchase agreement with accredited investors for an unsecured non-convertible note financing. The Company received $1,250,000 of gross proceeds in connection with the first tranche closing of this financing. The Company has the option, subject to certain conditions, to close on a second tranche of this financing. If the second tranche is closed, the Company will receive an additional $750,000 of gross proceeds. The option for the second tranche is exercisable by the Company at any time during the period commencing on the 10th trading day after the first tranche closing date and ending on the earlier of (x) the date no first tranche notes remain outstanding and (y) the six-month anniversary of the first tranche closing date. The Company expects the combined tranche financing of $2,000,000 should fund operations for approximately three months, into the third quarter of 2023.

28

Cash flows

The following table summarizes our sources and uses of cash for each of the periods presented:

	Six months Ended June 30,
	2023			2022
				(restated)
Cash used in operating activities	$	(1,960,653	)	$	(2,715,951	)
Cash used in investing activities		(72,634	)		(120,957	)
Cash provided by financing activities		1,165,000			6,187,258
Net (decrease) increase in cash	$	(868,287	)	$	3,350,350

Operating activities

During the six months ended June 30, 2023, operating activities used $1,960,653 of cash compared to $2,715,951 for the six months ended June 30, 2022 . This use of cash consisted primarily of employee compensation and benefit expense, general liability insurance, contractor compensation, and audit and legal fees. The Company completed their IPO in April 2002. Related to the IPO, the Company paid bonuses, funded a new director and officer insurance policy, and made a $123,828 payment to UCSF related to a license agreement milestone.

Investing activities

During the six months ended June 30, 2023, and 2022, investing activities used $72,634 and $120,957 of cash, respectively. These investing activities consisted almost entirely of patent and license maintenance.

Financing Activities

During the six months ended June 30, 2023, net cash provided by financing activities was $1,165,000, which included the issuance of an unsecured promissory note in the amount $1,250,000, net of $203,576 of issuance costs. During the six months ended June 30, 2022, net cash provided by financing activities was $6,187,258, which included the net of $8,552,318 (net of underwriter compensation and deductions but excluding $25,000 prepayment in 2021), of initial public offering proceeds, minus $365,060 of IPO-related cash issuance costs, and $2,000,000 repayment of promissory notes.

Funding requirements

Developing medical technology products is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate meaningful revenues. Accordingly, we may need to obtain substantial additional funds to achieve our business objectives.

Adequate additional funds may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of existing stockholders may be diluted. Any debt or preferred equity financing, if available, may involve agreements that include restrictive covenants that may limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business, and may require the issuance of warrants, which could potentially dilute existing stockholders’ ownership interests.

If we raise additional funds through licensing agreements and strategic collaborations with third parties, we may have to relinquish valuable rights to our technology, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds, we may be required to delay, limit, reduce and/or terminate development of our product candidates or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

29

Other contractual obligations and commitments

Our current office lease and sublease expired on June 30, 2022.  The Company does not have any contractual obligations not otherwise on our balance sheet as of June 30, 2023.

Off-balance sheet arrangements

We did not have, during the periods presented, and we do not currently have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.

Recently issued accounting pronouncements

We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our condensed financial statements appearing in this quarterly report, such standards will not have a material impact on our financial statements or do not otherwise apply to our operations.

Emerging growth company and smaller reporting company status

The JOBS Act permits an emerging growth company such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to “opt out” of this extended transition period and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for public entities. Accordingly, our financial statements may not be comparable to other public companies that do not elect the extended transition period.

We are also a “smaller reporting company” meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

30

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We have adopted and maintain disclosure controls and procedures (as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e) under the Exchange Act), that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods required under the SEC’s rules and forms and that the information is gathered and communicated to our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), to allow for timely decisions regarding required disclosure.

As required by Exchange Act Rule 13a-15, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15 as of the end of the period covered by this report. Based on the foregoing evaluation, our Chief Executive Officer and Chief Financial Officer concluded that due to our limited resources our disclosure controls and procedures are not effective in providing material information required to be included in our periodic SEC filings on a timely basis and to ensure that information required to be disclosed in our periodic SEC filings is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure about our internal control over financial reporting discussed below.

Changes in Internal Control over Financial Reporting

Our Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was not effective due to material weaknesses related to (1) a limited segregation of duties due to our lack of formal control documentation, limited resources, and the small number of employees, and (2) a lack of adequate accounting resources to properly account for complex accounting transactions. Management has determined that these control deficiencies constitute material weaknesses, which could result in material misstatements of significant accounts and disclosures that could result in a material misstatement to our interim or annual financial statements that would not be prevented or detected. In addition, due to limited staffing, we are not always able to detect minor errors or omissions in reporting.

31

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. We are not currently a party to any material legal proceedings, the adverse outcome of which, in our management’s opinion, individually or in the aggregate, could have a material adverse effect on the results of our operations or financial position. There are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial stockholder of more than 5% of our common stock is an adverse party or has a material interest adverse to our interest.

Item 1A. Risk Factors.

In addition to the information set forth in this Form 10-Q, you should carefully consider the risk factors disclosed in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 27, 2023, and an 10-K/A amendment filed June 12, 2023. There have been no material changes to our risk factors from those included in such Annual Report except as noted below. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

We are not currently in compliance with the certain continued listing requirements of the Nasdaq Capital Market and a delisting could limit the liquidity of our stock, increase its volatility and hinder our ability to raise capital.

As disclosed above (See Note 1 – Risks and Uncertainties) we are currently not in compliance with certain continued listing requirements of the Nasdaq Capital Market. Nasdaq has afforded the Company compliance periods with respect to these issues and the Company is working to retain compliance with all continued listing rules. There can be no assurance that the Company will be able to maintain the listing of its common stock on Nasdaq.

If our common stock is delisted by Nasdaq, our common stock may be eligible for quotation on an over-the-counter quotation system or on the pink sheets. Upon any such delisting, our common stock would become subject to the regulations of the SEC relating to the market for penny stocks. A penny stock is any equity security not traded on a national securities exchange that has a market price of less than $1.00 per share. The regulations applicable to penny stocks may severely affect the market liquidity for our common stock and could limit the ability of shareholders to sell securities in the secondary market. In such a case, an investor may find it more difficult to dispose of or obtain accurate quotations as to the market value of our common stock, and there can be no assurance that our common stock will be eligible for trading or quotation on any alternative exchanges or markets.

Delisting from Nasdaq could adversely affect our ability to raise additional financing through public or private sales of equity securities, would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our common stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

32

Item 6. Exhibits.

The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Quarterly Report are listed in the Exhibit Index below. The exhibits listed in the Exhibit Index are incorporated by reference herein.

Exhibit Number		Description of Document	Incorporated by reference from Form	Filing Date	Exhibit Number	Filed Herewith
1.1		Underwriting Agreement dated April 21, 2022	8-K	04-27-2022	1.1
3.1		Certificate of Incorporation of the Company	8-K	04-27-2022	3.1
3.2		Bylaws of the Company	8-K	04-27-2022	3.2
3.3		Certificate of Designation of Series A Preferred Stock	8-K	02-17-2023	3.1
4.1		Form of Common Stock Certificate	10-Q	06-06-2022	4.1
4.2		Form of Public Warrant	8-K	04-27-2022	4.1
4.3		Form of Representative’s Common Stock Purchase Warrant	8-K	04-27-2022	4.2
4.4		Description of Securities	10-Q	06-06-2022	4.4
10.1	#	Employment Agreement of Jeff Thramann	S-1/A	03-23-2022	10.1
10.2	#	Employment Agreement of Brent Ness	S-1/A	03-23-2022	10.2
10.3	#	Employment Agreement of John Lorbiecki	S-1/A	03-23-2022	10.3
10.4	#	Form of Aclarion, Inc. 2022 Equity Incentive Plan	S-1	01-06-2022	10.4
10.5		Senior Secured Bridge Note	S-1/A	03-04-2022	10.5
10.6		License Agreement with UCSF the Regents of the University of California	S-1	01-06-2022	10.6
10.7		Amendment to UC License Agreement	S-1/A	03-04-2022	10.7
10.8	**	NuVasive Amended and Restated Commission Agreement dated February 28, 2020	S-1/A	03-23-2022	10.8
10.9		Amended and Restated Investor Rights Agreement dated July 27, 2017	S-1/A	03-23-2022	10.9
10.10		First Amendment to Amended and Restated Investor Rights Agreement dated February 20, 2020	S-1/A	03-23-2022	10.10
10.11		NuVasive SAFE (Simple Agreement for Future Equity) dated February 28, 2020	S-1/A	03-23-2022	10.11
10.12	**	Right of First Offer Agreement	S-1/A	03-23-2022	10.12
10.13		First Amendment to Right of First Offer Agreement	S-1/A	03-23-2022	10.13
10.14		Second Amendment to Right of First Offer Agreement	S-1/A	03-23-2022	10.14
10.15		Convertible Note and Warrant Purchase Agreement	S-1/A	03-23-2022	10.16
10.16		Warrant Agent Agreement dated April 21, 2022	8-K	04-27-2022	10.1
10.17		Siemens Strategic Collaboration Agreement	S-1	01-06-2022	10.17
10.18	#	Aclarion, Inc. 2022 Equity Incentive Plan – Form of Option Grant Notice and Stock Option Agreement	S-1	01-06-2022	10.20

33

10.19		Aclarion, Inc. 2022 Equity Incentive Plan – Form of RSU Grant Notice and RSU Agreement	S-1	01-06-2022	10.21
10.20	#	Nocimed, Inc. 2015 Stock Plan	S-8	05-26-2022	99.4
10.21	#	Nocimed, Inc. 2015 Stock Plan – Form of Option Grant Notice and Stock Option Agreement	S-8	05-26-2022	99.5
10.22		Securities Purchase Agreement dated February 16, 2023 between Aclarion, Inc. and Jeffrey Thramann	8-K	02-17-2023	10.1
10.23		Form of Securities Purchase Agreement	8-K	05-17-2023	10.1
10.24		Form of Unsecured Non-Convertible Note	8-K	05-17-2023	10.2
10.25		Form of Common Stock Warrant	8-K	05-17-2023	10.3
10.26		Form of Registration Rights Agreement	8-K	05-17-2023	10.4
10.27		Waiver related to Unsecured Non-Convertible Notes	8-K	08-14-2023	10.1
31.1		Section 302 Certification by the Corporation’s Chief Executive Officer				X
31.2		Section 302 Certification by the Corporation’s Chief Financial Officer				X
32.1		Section 906 Certification by the Corporation’s Chief Executive Officer				X
32.2		Section 906 Certification by the Corporation’s Chief Financial Officer				X
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).

___________________________

#	Indicates management contract or compensatory plan.
**	Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.

34

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ACLARION, INC.
	By:	/s/ John Lorbiecki
		John Lorbiecki
		Chief Financial Officer (Principal Financial and Accounting Officer)
Date: August 25, 2023

35

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULES 13a-14(a) OR 15D-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Brent Ness, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2023 of Aclarion, Inc.
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)	(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

August 25, 2023

/s/ Brent Ness

Brent Ness

Chief Executive Officer

(Principal Executive Officer)

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULES 13a-14(a) OR 15D-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, John Lorbiecki, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2023 of Aclarion, Inc.
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)	(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

August 25, 2023

/s/ John Lorbiecki

John Lorbiecki

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Aclarion, Inc. (the “Company”) on Form 10-Q, for the period ended June 30, 2023 as filed with the Securities and Exchange Commission, I, Brent Ness, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Quarterly Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

August 25, 2023

/s/ Brent Ness

Brent Ness

Chief Executive Officer

(Principal Executive Officer)

EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Aclarion, Inc. (the “Company”) on Form 10-Q, for the period ended June 30, 2023 as filed with the Securities and Exchange Commission, I, John Lorbiecki, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Quarterly Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

August 25, 2023

/s/ John Lorbiecki

John Lorbiecki

Chief Financial Officer

(Principal Financial and Accounting Officer)

XML

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 25, 2023
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41358
Entity Registrant Name	ACLARION, INC.
Entity Central Index Key	0001635077
Entity Tax Identification Number	47-3324725
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8181 Arista Place
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Broomfield
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80021
City Area Code	(833)
Local Phone Number	275-2266
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,200,875
Common stock, par value $0.00001 per share [Member]
Title of 12(b) Security	Common stock, par value $0.00001 per share
Trading Symbol	ACON
Security Exchange Name	NASDAQ
Warrants, each exercisable for one share of Common stock [Member]
Title of 12(b) Security	Warrants, each exercisable for one share of Common stock
Trading Symbol	ACONW
Security Exchange Name	NASDAQ

XML

Condensed Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 604,518	$ 1,472,806
Restricted cash	10,000	10,000
Accounts receivable	10,365	18,569
Prepaids and other current assets	173,204	199,701
Total current assets	798,087	1,701,076
Non-current assets:
Property and equipment, net	2,342	3,346
Intangible assets, net	1,204,037	1,210,207
Total non-current assets	1,206,378	1,213,553
Total assets	2,004,466	2,914,629
Current liabilities:
Accounts payable	607,616	462,202
Accrued and other liabilities	513,000	226,469
Note payable, net of discount	118,838	0
Warrant liability	582,399	0
Derivative liability	172,389	0
Total current liabilities	1,994,242	688,671
Stockholders' equity
Common stock - $0.00001 par value, 200,000,000 authorized and 8,200,875 and 7,861,515 shares issued and outstanding (see Note 12)	82	79
Additional paid-in capital	42,028,310	41,596,032
Accumulated deficit	(42,018,169)	(39,370,153)
Total stockholders’ equity (deficit)	10,223	2,225,958
Total liabilities and stockholders’ equity (deficit)	$ 2,004,466	$ 2,914,629

XML

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares Issued	8,200,875	7,861,515
Common Stock, Shares Outstanding	8,200,875	7,861,515

XML

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue
Revenue	$ 17,072	$ 10,676	$ 42,542	$ 19,702
Cost of revenue	19,301	14,249	36,754	30,981
Gross profit (loss)	(2,229)	(3,573)	5,788	(11,279)
Operating expenses:
Sales and marketing	207,790	124,759	385,074	194,067
Research and development	250,006	353,226	454,405	558,029
General and administrative	946,175	1,731,190	1,753,774	2,222,473
Total operating expenses	1,403,971	2,209,175	2,593,253	2,974,569
(Loss) from operations	(1,406,200)	(2,212,748)	(2,587,465)	(2,985,848)
Other (expense):
Interest expense	(47,139)	(1,340,666)	(48,519)	(1,503,407)
Change in value of warrant and derivative liabilities	(11,800)	0	(11,800)	0
Other, net	583	(1,447)	(234)	(1,695)
Total other (expense)	(58,356)	(1,342,114)	(60,552)	(1,505,102)
(Loss) before income taxes	(1,464,557)	(3,554,862)	(2,648,017)	(4,490,950)
Income tax provision	0	0	0	0
Net (loss)	(1,464,557)	(3,554,862)	(2,648,017)	(4,490,950)
Dividends accrued for preferred stockholders	0	(128,208)	0	(415,523)
Net (loss) allocable to common stockholders	$ (1,464,557)	$ (3,683,070)	$ (2,648,017)	$ (4,906,473)

XML

Condensed Statements of Operations (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Earnings Per Share, Basic	$ (0.18)	$ (0.47)	$ (0.33)	$ (1.12)
Earnings Per Share, Diluted	$ (0.18)	$ (0.47)	$ (0.33)	$ (1.12)
Weighted Average Number of Shares Outstanding, Basic	8,287,669	7,821,515	8,119,982	4,373,668
Weighted Average Number of Shares Outstanding, Diluted	8,287,669	7,821,515	8,119,982	4,373,668

XML

Condensed Statements of Changes in Stockholders Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock Series A [Member]	Preferred Stock Series A 1 A 2 A 3 A 4 [Member]	Preferred Stock Series B B 1 [Member]	Preferred Stock Series B 2 B 3 [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 0	$ 62	$ 124	$ 0	$ 9	$ 19,054,234	$ (31,886,036)	$ (12,831,606)
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	0	6,247,695	12,434,500	5,812,809	905,685
Preferred stock dividend payable					$ 0	0	(287,315)	(287,315)
Share-based compensation					0	23,122	0	23,122
Net income (loss)					0	0	(936,088)	(936,088)
Ending balance, value at Mar. 31, 2022	$ 0	$ 62	$ 124	$ 0	$ 9	19,077,356	(33,109,439)	(14,031,887)
Shares, Outstanding, Ending Balance at Mar. 31, 2022	0	6,247,695	12,434,500	5,812,809	905,685
Beginning balance, value at Dec. 31, 2021	$ 0	$ 62	$ 124	$ 0	$ 9	19,054,234	(31,886,036)	(12,831,606)
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	0	6,247,695	12,434,500	5,812,809	905,685
Net income (loss)								(4,490,950)
Ending balance, value at Jun. 30, 2022	$ 0	$ 0	$ 0	$ 0	$ 78	41,032,001	(36,792,509)	4,239,570
Shares, Outstanding, Ending Balance at Jun. 30, 2022	0	0	0	0	7,821,515
Beginning balance, value at Mar. 31, 2022	$ 0	$ 62	$ 124	$ 0	$ 9	19,077,356	(33,109,439)	(14,031,887)
Shares, Outstanding, Beginning Balance at Mar. 31, 2022	0	6,247,695	12,434,500	5,812,809	905,685
Preferred stock dividend payable							(128,208)	(128,208)
Share-based compensation						701,505		701,505
Net income (loss)							(3,554,862)	(3,554,862)
Issuance of warrants						1,280		1,280
Exercise of convertible note warrants					1	(1)	0	0
Conversion of preferred dividends payable to common stock					10	4,272,411		4,272,420
Conversion of preferred stock to common stock		$ (62)	$ (124)		$ 33	7,102,441		7,102,287
Stock Issued During Period, Shares, Conversion of Convertible Securities		(6,247,695)	(12,434,500)	(5,812,809)	3,279,117
Conversion of accrued interest on promissory notes					$ 4	1,855,154		1,855,158
Issuance of common stock and warrants related to IPO, net issuance costs					22	8,552,318		8,552,340
Issuance of warrants						(530,463)		(530,463)
Exercise of Convertible Note Warrants, Shares					60,408
Conversion of Preferred Dividends Payable to Common Stock, Shares					984,537
Conversion of Accrued Interest on Promissory Notes, Shares					426,768
Issuance of Common Stock and Warrants Related to IPO Net Issuance Costs, Shares					2,165,000
Ending balance, value at Jun. 30, 2022	$ 0	$ 0	$ 0	$ 0	$ 78	41,032,001	(36,792,509)	4,239,570
Shares, Outstanding, Ending Balance at Jun. 30, 2022	0	0	0	0	7,821,515
Beginning balance, value at Dec. 31, 2022	$ 0	$ 0	$ 0	$ 0	$ 79	41,596,032	(39,370,153)	2,225,958
Shares, Outstanding, Beginning Balance at Dec. 31, 2022	0	0	0	0	7,861,515
Share-based compensation						82,531		82,531
Net income (loss)					0	0	(1,183,460)	(1,183,460)
Proceeds from sale of Series A preferred stock	$ 1,000							1,000
Preferred Stock Redemption Discount, Shares	1
Redemption of Series A Preferred stock	$ (1,000)							(1,000)
Preferred Stock Redemption Premium, Shares	(1)
Ending balance, value at Mar. 31, 2023	$ 0	$ 0	$ 0	$ 0	$ 79	41,678,563	(40,553,613)	1,125,029
Shares, Outstanding, Ending Balance at Mar. 31, 2023	0	0	0	0	7,861,515
Beginning balance, value at Dec. 31, 2022	$ 0	$ 0	$ 0	$ 0	$ 79	41,596,032	(39,370,153)	2,225,958
Shares, Outstanding, Beginning Balance at Dec. 31, 2022	0	0	0	0	7,861,515
Net income (loss)								(2,648,017)
Ending balance, value at Jun. 30, 2023	$ 0	$ 0	$ 0	$ 0	$ 82	42,028,310	(42,018,169)	10,223
Shares, Outstanding, Ending Balance at Jun. 30, 2023	0	0	0	0	8,200,875
Beginning balance, value at Mar. 31, 2023	$ 0	$ 0	$ 0	$ 0	$ 79	41,678,563	(40,553,613)	1,125,029
Shares, Outstanding, Beginning Balance at Mar. 31, 2023	0	0	0	0	7,861,515
Share-based compensation					$ 0	136,631	0	136,631
Net income (loss)							(1,454,557)	(1,464,557)
Issuance of warrants						37,500		37,500
Issuance of common shares					$ 3	175,616		175,619
Stock Issued During Period, Shares, New Issues					339,360
Ending balance, value at Jun. 30, 2023	$ 0	$ 0	$ 0	$ 0	$ 82	$ 42,028,310	$ (42,018,169)	$ 10,223
Shares, Outstanding, Ending Balance at Jun. 30, 2023	0	0	0	0	8,200,875

XML

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net (loss)	$ (2,648,017)	$ (4,490,950)
Adjustments to reconcile net (loss) to net cash used in operation activities:
Depreciation and amortization	79,809	69,705
Share-based compensation	219,162	724,627
Amortization of deferred issuance costs	28,520	0
Change in fair value of warrants and derivative	11,800	0
Non-cash interest related to bridge funding	14,346	0
Loss on disposal of furniture and equipment	0	1,886
Interest conversion discount settled in equity	0	1,299,508
Change in assets and liabilities
Accounts receivable	1,414	1,243
Prepaids and other current assets	33,287	(448,434)
Accounts payable	57,914	119,072
Accrued and other liabilities	241,110	(193,320)
Accrued interest on promissory and convertible notes		200,712
Net cash (used in) operations	(1,960,653)	(2,715,951)
Cash flows from investing activities
Intangible assets - Patents	(72,634)	(121,957)
Proceeds from sale of furniture	0	1,000
Net cash (used in) investing activities	(72,634)	(120,957)
Cash flows from financing activities
Proceeds from bridge funding	1,250,000	0
IPO/bridge funding issuance costs	(85,000)	(365,060)
Repayment of promissory notes	0	(2,000,000)
Issuance of common stock and warrants related to IPO, net deductions	0	8,552,318
Proceeds from sale of Series A preferred stock	1,000	0
Redemption of Series A Preferred stock	(1,000)	0
Net cash provided by financing activities	1,165,000	6,187,258
Net cash increase (decrease) for period	(868,287)	3,350,350
Cash and restricted cash, beginning of period	1,482,806	452,530
Cash and restricted cash, end of period	614,518	3,802,880
Non- cash activities
Dividends accrued on preferred shares	0	415,523
Conversion of preferred stock to common stock	0	25,754,379
Conversion of preferred stock dividends to common stock	0	4,272,421
Conversion of accrued interest on promissory notes to common stock and warrants	0	1,856,438
Issuance of underwriter's warrants related to IPO	0	199,246
Designation of prepaid expenses to IPO issuance costs	0	165,403
Fair value of warrants and derivative related to bridge funding	742,988	0
Issuance of commitment shares related to bridge funding	175,619	0
Accrued debt issuance costs related to bridge funding	118,575
Issuance of warrants related to bridge funding	37,500
Original issuance discount (15%) related to bridge funding	$ 187,500

XML

THE COMPANY AND BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

THE COMPANY AND BASIS OF PRESENTATION

NOTE 1. THE COMPANY AND BASIS OF PRESENTATION

The Company

Aclarion, Inc., formerly Nocimed, Inc., (the “Company”, “we”, or “Aclarion”) is a healthcare technology company that leverages magnetic resonance spectroscopy (“MRS”), and a proprietary biomarker to optimize clinical treatments. The Company was formed in February 2015, is incorporated in Delaware, and has its principal place of business in Broomfield, Colorado.

Basis of Presentation

The accompanying condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information required by U.S. GAAP for complete financial statements. The interim condensed financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair representation of the results for the periods presented and should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2022, which include a complete set of footnote disclosures, including our significant accounting policies. The December 31, 2022 condensed balance sheet was derived from the December 31, 2022 audited financial statements. They should be read in conjunction with the financial statements and notes thereto included in our Annual report on Form 10-K/A, filed with the SEC on June 12, 2023. The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Risks and Uncertainties

The Company is subject to various risks and uncertainties frequently encountered by companies in the early stages of development. Such risks and uncertainties include, but are not limited to, its limited operating history, competition from other companies, limited access to additional funds, dependence on key personnel, and management of potential rapid growth. To address these risks, the Company must, among other things, develop its customer base; implement and successfully execute its business and marketing strategy; develop follow-on products; provide superior customer service; and attract, retain, and motivate qualified personnel. There can be no guarantee that the Company will be successful in addressing these or other such risks.

On March 3, 2023, we received a letter from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. At December 31, 2022, we reported stockholders’ equity of $1,787,751 (prior to restatement, see Note 4 of form 10-K/A filed June 12, 2023), and, as a result, we did not satisfy Listing Rule 5550(b)(1). Nasdaq allowed us a period of 45 calendar days from the date of the letter, or until April 17, 2023, to submit a plan to regain compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). We submitted such a plan to Nasdaq on April 12, 2023. On April 20, 2023, the Company received a letter from Nasdaq granting us an additional 180-day period, or until August 30, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Separately, on August 4, 2023, we received a notice from Nasdaq indicating that we were not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). This notice indicated that the Company will be provided 180 calendar days in which to regain compliance. If at any time during this 180 calendar day period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq staff (the “Staff”) will provide the Company with a written confirmation of compliance and the matter will be closed.

Alternatively, if the Company fails to regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, the Company may be eligible for an additional 180 calendar day compliance period, provided (i) it meets the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the Bid Price Requirement) and (ii) it provides written notice to Nasdaq of its intention to cure this deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event the Company does not regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, and if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is not otherwise eligible, the Staff will provide the Company with written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Company intends to consider all options to regain compliance with all Nasdaq continued listing requirements.

Initial Public Offering

On April 26, 2022, the Company completed its initial public offering (“IPO”) of 2,165,000 units, at a public offering price of $4.35 per unit. Each unit consisted of (i) one share of common stock and (ii) one common stock warrant with an exercise price of $4.35 per share. Following the commencement of the IPO, the underwriters partially exercised their over-allotment option and purchased an additional 324,750 common stock warrants. After deducting underwriter's commissions and expenses, the Company received net proceeds of approximately $8.6 million, and our common stock and warrants started trading on Nasdaq under the ticker symbols “ACON” and “ACONW”, respectively.

Concurrently with the IPO, holders of the Company’s promissory notes, along with accrued interest, and preferred stock, along with accrued dividends, and certain outstanding common stock warrants were converted into 4,750,830 shares of the Company’s common stock and 426,768 common stock warrants.

In connection with the IPO, we issued to the representative of the underwriters a common stock warrant for 173,200 shares with an exercise price of $5.44 per share. The representative's warrants were exercisable commencing October 26, 2022, and will expire on April 26, 2027.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The financial statements include some amounts that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and valuation of warrants and options to purchase shares of the Company's common stock. These estimates may be adjusted as more current information becomes available, and any adjustment could be significant.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1 - Unadjusted quoted prices in active markets for identical instruments that are accessible by the Company on the measurement date.

Level 2 - Quoted prices in markets that are not active or inputs which are either directly or indirectly observable.

Level 3 - Unobservable inputs for the instrument requiring the development of assumptions by the Company.

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The carrying values of the Company’s financial instruments including cash equivalents, restricted cash, accounts receivable, and accounts payable are approximately equal to their respective fair values due to the relatively short-term nature of these instruments. The Company’s warrant liabilities and derivative liabilities are estimated using level 3 inputs (see Note 3).

Derivative Financial Instruments

The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expenses), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at June 30, 2023 and December 31, 2022. The Company maintains cash deposits at several financial institutions, which are insured by the FDIC up to $250,000. The Company’s cash balance may at times exceed these limits. On June 30, 2023, and December 31, 2022, the Company had $81,088 and $1,229,863, respectively, in excess of federally insured limits. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company maintains no international bank accounts. As of June 30, 2023, the Company reported cash of $604,518 and restricted cash of $10,000 which aggregates to $614,518 and is reported on the statement of cash flows as cash and restricted cash.

Accounts Receivable, Less Allowance for Doubtful Accounts

The Company estimates an allowance for doubtful accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was $0 on June 30, 2023, and December 31, 2022.

Revenue Recognition

Revenues are recognized when a contract with a customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report, the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees. To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the billing schedules in its sales arrangements. Payment terms range generally from prepayment to 90 days from the date of invoice.

Liquidity, Capital Resources and Going Concern

The Company had a cash and restricted cash balance of $614,518 as of June 30, 2023. On May 16, 2023, we entered into a securities purchase agreement with accredited investors for unsecured non-convertible note financing. The Company received $1,250,000 of gross proceeds in connection with the first tranche closing of this financing. The Company has the option, subject to certain conditions, to close on a second tranche of this financing. If the second tranche is closed, the Company will receive an additional $750,000 of gross proceeds. This interim bridge funding should allow the Company to operate into the third quarter of 2023. Management is actively managing our cash position and working to secure longer-term funding.

As a result of the Company’s recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.

Share-Based Compensation

The Company issues stock-based compensation awards to employees and directors in the form of stock options. The Company measures and recognizes compensation expense for all stock-based awards based on the awards’ fair value. Share-based compensation for stock options awards is measured on the date of grant using a Black-Scholes-Merton option pricing model.

Awards vest either on a graded schedule or at the grant date. The Company determines the fair value of each award as a single award and recognizes the expense on a straight-line basis over the service period of the award, which is generally the vesting period. The exercise price of stock options granted is equal to the fair market value of the Company’s common stock on the date of grant. Stock options expire ten years from the date of grant.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period to comply with certain new or revised accounting standards that have different effective dates for public and private companies.

XML

FAIR VALUE MEASUREMENTS

6 Months Ended

Jun. 30, 2023

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 3. FAIR VALUE MEASUREMENTS

In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the outstanding warrants, certain embedded redemption features associated with the senior note to Aclarion, Inc. on a recurring basis to determine the fair value of the liability.

	Fair value measured as of June 30, 2023
	Fair value on June 30, 2023		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Warrant liability	$	582,399	$	–	$	–	$	582,399
Derivative Liability		172,389		–		–		172,389
Total Fair value	$	754,788	$	–	$	–	$	754,788

There were no transfers between Level 1, 2, and 3 during the period ended June 30, 2023, and the year ended December 31, 2022.

The following table presents changes in Level 3 liabilities measures at fair value for the period ended June 30, 2023, and the year ended December 31, 2022. Both observable and unobservable inputs were used to determine the fair value positions that the Company has classified within the Level 3 category. 

	Warrant Liability		Derivative Liability		Total
Balance - January 1, 2023	$	–	$	–	$	–
Additional warrant and derivative liability		579,818		163,170		742,988
Change in fair value		2,581		9,219		11,800
Balance - June 30, 2023	$	582,399	$	172,389	$	754,788

The fair value of the embedded derivative liabilities associated with the Senior Notes Payable was estimated using a probability weighted discounted cash flow model to measure the fair value. This involves significant Level 3 inputs and assumptions including an (i) estimated probability and timing of certain financing events and event of default, and (ii) the Company’s risk-adjusted discount rate.

The fair value of the warrants to purchase shares of common stock was estimated using a Monte Carlo simulation using the following assumptions. 

	As of Issuance		As of June 30, 2023
	Warrant Liability		Warrant Liability
Strike Price	$	0.63	$	0.63
Contractual term (years)		5.0		5.0
Volatility (annual)		80.0%		80.0%
Risk-free rate		3.52%		4.15%
Floor Financing price	$	0.50	$	0.50

XML

RECENT ACCOUNTING PRONOUNCEMENTS

6 Months Ended

Jun. 30, 2023

Accounting Changes and Error Corrections [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

NOTE 4. RECENT ACCOUNTING PRONOUNCEMENTS

In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”), which simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. The guidance also modifies how certain convertible instruments, that may be settled in cash or shares, impact the calculation of diluted earnings per share. ASU 2020-06 allows for a modified or full retrospective method of transition. This update is effective for emerging growth companies following private company adoption dates in fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company adopted this standard as of April 1, 2022, using the modified retrospective approach. The adoption of this guidance did not have a material impact on the accompanying unaudited condensed consolidated financial statements.

On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as amended, which replaces the incurred loss methodology with an expected loss methodology, that is referred to as a current expected loss methodology (CECL). CECL was required to be implemented for small business reporting companies after December 31, 2022. The measurement of expected losses under the CECL methodology is applicable to financial assets measured at amortized cost, including trade receivables, loan receivables and held-to-maturity debt securities. It also applies to off balance sheet credit exposures not accounted for as insurance, loan commitments, standby letters of credit, financial guarantees, and similar instruments and net investment in leases, as accounted for by the lessor under ASC 842. In addition, ASC 326 made changes to the available for-sale debt securities. One such change is to require credit losses be accounted for as an allowance instead of a write-down on available for-sale securities that management does not intend to sell, or believes it is more likely than not that they will be required to sell.

The Company has adopted ASC 326 using the retrospective approach for all financial assets measured at amortized cost, which consists of trade receivables. The Company estimates the likelihood of collection considering trade receivables-based factors such as the creditworthiness of its customers. There are no off-balance sheet assets or guarantees. The Company recorded no change to retained earnings due to the adoption of ASC 326.

As of this date, the Company has not purchased, nor does it intend to purchase, debt securities, eroded or financial assets, or leases within the scope of the pronouncement. If it does, it will use the prospective transition approach.

XML

REVENUE

6 Months Ended

Jun. 30, 2023

Revenue from Contract with Customer [Abstract]

REVENUE

NOTE 5. REVENUE

Contract Balances

The timing of revenue recognition, billings, and cash collections may result in trade, unbilled receivables, and deferred revenues on the balance sheets. At times, revenue recognition may occur before the billing, resulting in an unbilled receivable, which would represent a contract asset. The contract asset would be a component of accounts receivable and other assets for the current and non-current portions, respectively. A contract liability is recorded when the Company receives payments prior to earning the revenue.

XML

CORRECTION OF ERRORS IN 2022 INTERIM FINANCIAL INFORMATION

6 Months Ended

Jun. 30, 2023

Accounting Changes and Error Corrections [Abstract]

CORRECTION OF ERRORS IN 2022 INTERIM FINANCIAL INFORMATION

NOTE 6. CORRECTION OF ERRORS IN 2022 INTERIM FINANCIAL INFORMATION

Subsequent to the initial issuance of the Company's 2022 financial statements on February 27, 2023, management discovered that the previously issued interim financial statements for the three and six months ended June 30, 2022 and the nine months ended September 30, 2022 did not properly record the following items in accordance with US GAAP:

(a)	the statement of cash flows inaccurately presented costs associated with the Initial Public Offering in the operating section, instead of the financing section and
(b)	a charge of $152,653 for the exercise of warrants at the time of the Initial Public Offering was incorrectly recorded as expense.

Additionally, management introduced various reclassifications within the statement of cash flows to present in accordance with US GAAP. The following tables summarize the impacts of these error corrections on the Company's interim financial statements for each of the interim periods presented below:

Condensed Balance Sheets	For the six months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Total assets	$	5,620,989		$	–		$	5,620,989
Total current liabilities		1,381,419			–			1,381,419
Additional paid-in capital		41,184,654			(152,653	)		41,032,001
Accumulated deficit		(36,945,162	)		152,653			(36,792,509	)
Other		78			–			78
Total stockholders’ equity		4,239,570			–			4,239,570
Total liabilities and stockholders’ equity	$	5,620,989		$	–		$	5,620,989

Condensed Statements of Operations	For the six months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Gross profit (loss)	$	(11,279	)	$	–		$	(11,279	)
Sales and marketing		194,067			–			194,067
Research and development		558,029			–			558,029
General and administrative		2,375,126			(152,653	)		2,222,473
Total operating expenses		3,127,222			(152,653	)		2,974,569
Total other income (expense)		(1,505,102	)		–			(1,505,102	)
Net income (loss)	$	(4,643,603	)	$	152,653		$	(4,490,950	)
Net (loss) allocable to common stockholders	$	(5,059,126	)	$	152,653		$	(4,906,473	)
(Loss) per share	$	(1.16	)	$	0.04		$	(1.12	)
Weighted Average common shares outstanding		4,363,600			10,068			4,373,668

Condensed Statements of Operations	For the three months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Gross profit (loss)	$	(3,573	)	$	–		$	(3,573	)
Sales and marketing		124,759			–			124,759
Research and development		353,226			–			353,226
General and administrative		1,883,843			(152,653	)		1,731,190
Total operating expenses		2,361,828			(152,653	)		2,209,175
Total other income (expense)		(1,342,114	)		–			(1,342,114	)
Net income (loss)	$	(3,707,515	)	$	152,653		$	(3,554,862	)
Net (loss) allocable to common stockholders	$	(3,835,723	)	$	152,653		$	(3,683,070	)
(Loss) per share	$	(0.49	)	$	0.02		$	(0.47	)
Weighted Average common shares outstanding		7,821,515			–			7,821,515

Condensed Statements of Cash Flows	For the six months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Net income (loss)	$	(4,643,603	)	$	152,653		$	(4,490,950	)
Adjustments to reconcile net income (loss) to net cash used in operation activities
Depreciation and amortization		94,705			(25,000	)		69,705
Non-cash charge settled in equity		–			1,299,507			1,299,507
Prepaids and other current assets		(308,052	)		(140,382	)		(448,434	)
Accrued and other liabilities		728,399			(921,718	)		(193,320	)
Other		1,047,540			–			1,047,540
Net cash (used in) operations		(3,081,011	)		365,060			(2,715,951	)
Net cash (used in) investing activities		(120,957	)		–			(120,957	)
IPO Issuance costs		–			(365,060	)		(365,060	)
Others		6,552,318			–			6,552,318
Net cash provided by financing activities		6,552,318			(365,060	)		6,187,258
Net cash increase (decrease) for period	$	3,350,350		$	–		$	3,350,350

Condensed Statements of Changes in Stockholders’ Equity	June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Common Stock	$	78		$	–		$	78
Additional paid-in capital		41,184,654			(152,653	)		41,032,001
Accumulated deficit		(36,945,162	)		152,653			(36,792,509	)
Total stockholders’ equity	$	4,239,570		$	–		$	4,239,570

XML

SUPPLEMENTAL FINANCIAL INFORMATION

6 Months Ended

Jun. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUPPLEMENTAL FINANCIAL INFORMATION

NOTE 7. SUPPLEMENTAL FINANCIAL INFORMATION

Balance Sheets

Accrued and other liabilities: 

	June 30, 2023		December 31, 2022
Accrued bonus	$	291,812	$	134,704
Accrued expenses		153,805		35,922
Accrued payroll and related liabilities		47,023		46,250
Accrued interest		14,346		–
Other accrued liabilities		6,014		9,593
	$	513,000	$	226,469

XML

LEASES

6 Months Ended

Jun. 30, 2023

Leases

LEASES

NOTE 8. LEASES

Rent expense for the three months ended June 30, 2023, and 2022, was $0 and $16,425, respectively. Rent expense for the six months ended June 30, 2023, and 2022, was $0 and $32,510, respectively.

The Company entered into a subleasing agreement in 2021 and realized $0 and $26,340 of sublease income for the six months ended June 30, 2023, and 2022. Both the lease and sublease are netted within the general & administrative line item in the Condensed Statements of Operations. Our current office lease and sublease expired on June 30, 2022.

XML

INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 9. INTANGIBLE ASSETS

The Company’s intangible assets are as follows: 

	June 30, 2023			December 31, 2022
Patents and licenses	$	2,220,363		$	2,147,728
Other		5,017			5,017
		2,225,380			2,152,745
Less: accumulated amortization		(1,021,343	)		(942,538	)
Intangible assets, net	$	1,204,037		$	1,210,207

Patents and licenses costs are accounted for as intangible assets and amortized over the life of the patent or license agreement and charged to research and development.

Amortization expense related to purchased intangible assets was $39,940 and $33,396 for the three months ended June 30, 2023, and 2022, respectively. Amortization expense related to purchased intangible assets was $78,805 and $66,583 for the six months ended June 30, 2023, and 2022, respectively.

Patents and trademarks are reviewed at least annually for impairment. No impairment was recorded through June 30, 2023, and December 31, 2022, respectively.

Future amortization of intangible assets is as follows: 

2023	$	81,096
2024		162,191
2025		162,191
2026		162,191
2027 and beyond		636,368
Total	$	1,204,037

XML

SHORT TERM NOTES, CONVERTIBLE DEBT, AND DERIVATIVE LIABILITIES

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

SHORT TERM NOTES, CONVERTIBLE DEBT, AND DERIVATIVE LIABILITIES

NOTE  10. SHORT TERM NOTES, CONVERTIBLE DEBT, AND DERIVATIVE LIABILITIES

Senior Notes Payable

In May 2023, the Company issued $1,437,500 unsecured senior notes that mature on May 16, 2024 (“the Senior Notes Payable”), for cash proceeds of $1,250,000. The Senior Notes Payable contain an original issue discount of 15.0% and accrue interest at an annual rate of 8.0%. The Company incurred issuance costs, recorded as deferred financing costs, of $203,575 relating to due diligence and legal costs associated with the transaction.

The Company evaluated the embedded redemption and contingent interest features in the Senior Notes Payable to determine if such features were required to be bifurcated as an embedded derivative liability. In accordance with ASC 815-40, Derivatives and Hedging Activities, the embedded redemption features and contingent interest feature were accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value at each reporting date. The Company fair valued such derivative liabilities and recorded a debt discount at issuance of $163,170.

The Company issued warrants to purchase 1,232,156 shares of common stock to the holders (the “Senior Notes Warrants”) with an exercise price of $0.6262 per share. The Company accounted for the warrants in accordance with the guidance contained in ASC 815 “Derivatives and Hedging” whereby under that provision these warrants did not meet the criteria for equity treatment and were recorded as a liability. As such, these warrants are recorded at fair value as of each reporting date with the change in fair value reported within other income in the accompanying consolidated statements of operations as “Change in fair value of warrant liability” until the warrants are exercised, expired or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity. The fair value of the Senior Notes Warrants at issuance was $579,818 and was recorded as a debt discount.

In connection with the issuance of the Senior Notes Payable, the Company paid a commitment fee in the form of 339,360 shares of unregistered common stock to the holders. The commitment fee has a fair value at issuance of $175,619 and is recorded as a deferred financing cost.

The resulting debt discounts from the derivative liabilities, warrant liabilities and deferred financing costs were presented as a direct deduction from the carrying amount of that debt liability and amortized to interest expense using the effective interest rate method. For the six months ended June 30, 2023, the Company recognized $28,520 in amortization of debt discounts and deferred financing costs which is recorded in interest expense.

The following table reconciles the Senior Notes Payable and unamortized deferred financing costs and debt discounts relating to the derivative liabilities and warrant liabilities.

Note payable, net of discount: 

	June 30, 2023			December 31, 2022
Note Payable	$	1,437,500		$	–
Less: Unamortized Discounts and Deferred Financing Costs					–
Warrants		(567,543	)		–
Derivative		(159,716	)		–
Issuance cost		(591,403	)		–
		(1,318,662	)		–
	$	118,838		$	–

Promissory Notes Payable

In June 2021, the Company issued $2.0 million of promissory notes that matured at the earlier of the consummation of a Qualified Financing or May 31, 2022. The promissory notes incorporated the following major attributes: secured by a lien and security interest on substantially all of the Company’s assets; interest accrues at 33%; holder option to convert the accrued interest into the Company securities being offered in a Qualified Financing at 30% (i.e. 70% discount) of the price being paid by other investors in the Qualified Financing; and automatic conversion in the case of a Qualifying IPO of the accrued interest into the Company securities being offered in the Qualifying IPO at 30% (70% discount) of the price being paid by other investors in the Qualifying IPO. If the promissory notes remained outstanding after May 31, 2022, the Company had the option to extend the promissory notes upon the payment of an extension fee, which consisted of 150,000 warrants (20,080 warrants post-split) with a five-year term, to purchase shares of the Company’s common stock at a price of $ 0.01 per share ($0.0747 post-split).

On April 21, 2022, the registration statement for our IPO was declared effective. In connection with the effectiveness of the IPO registration statement, all accrued interest on the Company's outstanding secured promissory notes was converted into (i) 426,768 post-split common shares and (ii) 426,768 post-split common stock warrants, with a $1,299,507 beneficial conversion rate charged to interest expense.

On April 27, 2022, the Company used $2 million of the IPO proceeds to retire all outstanding secured promissory notes.

XML

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 11. COMMITMENTS AND CONTINGENCIES

Royalty Agreement

The Company has an exclusive license agreement with the Regents of the University of California to make, use, sell and otherwise distribute products under certain of the Regents of the University of California’s patents anywhere in the world. The Company is obligated to pay a minimum annual royalty of $50,000, and an earned royalty of 4% of net sales. The minimum annual royalty will be applied against the earned royalty due for the calendar year in which the minimum payment was made. The license agreements expire upon expiration of the patents and may be terminated earlier if the Company so elects. The U.S. licensed patents that are currently issued expire between 2026 and 2029, without considering any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. The Company recorded royalty costs of $12,500 for the three months ended June 30, 2023, and 2022, respectively, and $25,000 for the six months ended June 30, 2023, and 2022, respectively, as Cost of Revenue.

Litigation

To date, the Company has not been involved in legal proceedings arising in the ordinary course of its business. If any legal proceeding occurs, the Company will record a provision for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated, although litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position and cash flows.

XML

STOCKHOLDERS’ EQUITY

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 12. STOCKHOLDERS’ EQUITY

The Company filed an Amended and Restated Certificate of Incorporation on April 21, 2022, as part of the IPO. The Company is authorized to issue two classes of stock to be designated, respectively, “common stock” and “preferred stock.” The total number of shares which the Company is authorized to issue is two hundred twenty million (220,000,000) shares. Two hundred million (200,000,000) shares are authorized to be common stock, having a par value per share of $0.00001. Twenty million (20,000,000) shares are authorized to be preferred stock, having a par value per share of $0.00001. As of June 30, 2023, the Company had 8,200,875 common shares outstanding.

Stockholders’ Vote – Reverse stock split

We held a special meeting of stockholders on March 24, 2023. At the special meeting, our stockholders approved one proposal, which was to grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-five (1-for-5) to a maximum of a one-for-fifty (1-for-50) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal was approved by stockholders.

Series A-1, A-2, A-3, A-4, B, B-1, B-2, and B-3 Preferred Stock

Prior to the IPO, the Company had authorized two classes of shares. These classes included shares of common stock and preferred stock. There was one authorized series of shares of common stock and eight existing authorized series of preferred stock: Series A-1, A-2, A-3, A-4, B, B-1, B-2, and B-3.

The Series B, B-1, B-2 and B-3 preferred stock earned a dividend rate is 6.0%. Dividends were cumulative. The accrued and unpaid dividends were payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock.

The preferred shares converted to common shares on a 1:1 pre-split basis immediately prior to the Stock Split on April 21, 2022.

Series A Preferred Stock

In February 2023 the Company sold one (1) share of the Company’s newly designated Series A preferred stock to Jeffrey Thramann, the Company’s Executive Chairman, for a purchase price of $1,000. The share of Series A preferred stock had proportional voting rights that were limited to the proposal to approve a reverse stock split of the Company’s common stock. Following the March 24, 2023, special meeting, the Company redeemed the one outstanding share of Series A preferred stock on March 28, 2023, in accordance with its terms. The redemption price was $1,000. No Series A preferred stock remains outstanding.

Warrants

Pre-Funded Placement Agent Warrants

During the six months ended June 30, 2023, the Company issued 54,340 shares of common stock in the form of pre-funded warrants to the placement agent in connection with the Senior Notes Payable issuance discussed in Note 10. The value of the warrants was recorded as a debt discount on the Notes.

Warrants issued with Convertible Notes

During the years ended December 31, 2022, and 2021, the Company issued 17,286 and 58,846 warrants, respectively, to certain investors who participated over an agreed investment minimum amount in the purchase of our convertible notes. The value of the warrants was recorded as a debt discount and expensed based on the fair value. Just prior to the IPO, these common stock warrants were exercised on a net share basis for 60,408 common shares (451,245 pre-split shares).

Warrants issued in connection with the IPO

In connection with the Company’s IPO, all accrued interest on the Company's outstanding secured promissory notes were converted into (i) 426,768 post-split common shares and (ii) 426,768 post-split common stock warrants, with beneficial conversion rates charged to interest expense upon conversion. These warrants have an exercise price of $4.35 per share.

In the IPO, the Company sold 2,165,000 units, at a public offering price of $4.35 per unit. Each unit consisted of (i) one share of common stock and (ii) one common stock warrant (“IPO Warrant”) with an exercise price of $4.35 per share. The common stock and the IPO Warrants were immediately separable and issued separately in the offering. The IPO Warrants are listed and tradeable on the NASDAQ stock market, immediately exercisable at the option of the holder, and expire five years from the date of issuance.

On April 22, 2022, the IPO underwriters partially exercised their over-allotment option for an additional 324,750 IPO Warrants.

In connection with the IPO, we issued to the representative of the underwriters common stock warrants for 173,200 shares with an exercise price of $5.44 per share. The representative's warrants are exercisable commencing October 26, 2022, and will expire on April 26, 2027.

The Company evaluated the terms of all warrants issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging. Since the Company determined that the warrants were equity classified, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance of proceeds to additional paid in capital.

As of June 30, 2023, 2,489,750 IPO Warrants were outstanding.

XML

NET LOSS PER SHARE OF COMMON STOCK

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

NET LOSS PER SHARE OF COMMON STOCK

NOTE 13. NET LOSS PER SHARE OF COMMON STOCK

Basic and diluted net loss per share is computed by dividing net loss attributable to stockholders by the weighted average number shares of common stock outstanding during the period and shares issuable for vested restricted stock units. Potentially dilutive outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to stockholders follows:  

	Three Months Ended June 30,
	2023			2022
Numerator:
Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share	$	(1,464,557	)	$	(3,683,070	)
Denominator:
Weighted average shares outstanding used to compute basic and dilutive loss per share		8,087,755			–
Weighted average shares issuable for vested restricted stock units		199,914			–
		8,287,669			7,821,515

	Six Months Ended June 30,
	2023			2022
Numerator:
Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share	$	(2,648,017	)	$	(4,906,473	)
Denominator:
Weighted average shares outstanding used to compute basic and dilutive loss per share		7,974,635			4,373,668
Weighted average shares issuable for vested restricted stock units		145,347			–
		8,119,982			4,373,668

The following outstanding potentially dilutive securities were excluded from the weighted average calculation of dilutive loss per share attributable to common stockholders because their impact would have been antidilutive for the period presented: 

	June 30, 2023		June 30, 2022
Series A and B convertible preferred stock		–		1,639,559
Warrants		3,518,550		1,570,236
Restricted stock units		692,422		–
Stock options		2,738,820		2,351,510
		6,949,792		5,561,305

XML

STOCK BASED COMPENSATION

6 Months Ended

Jun. 30, 2023

Share-Based Payment Arrangement [Abstract]

STOCK BASED COMPENSATION

NOTE 14. STOCK BASED COMPENSATION

2022 Aclarion Equity Incentive Plan

On April 21, 2022, in connection with the IPO, the Company adopted the 2022 Aclarion Equity Incentive Plan, or “2022 Plan”. Our board of directors has appointed the compensation committee of our board of directors as the committee under the 2022 Plan with the authority to administer the 2022 Plan. The initial aggregate number of our shares of common stock that may be issued under the 2022 Plan was 2,000,000 shares, subject to adjustments as described in the 2022 Plan.

The 2022 Plan contains an “evergreen” provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased on the first day of each year beginning in 2023 equal to the lesser of (a) five percent (5%) of the shares of stock outstanding on the last day of the immediately preceding fiscal year and (b) such smaller number of shares of stock as determined by our board of directors. On January 1, 2023, an additional 393,076 shares were added to the 2022 Plan pursuant to the evergreen provision. As a result, the aggregate number of our shares of common stock that may be issued under the 2022 Plan has been increased to 2,393,076 shares.

Options granted under the 2022 Plan may be incentive stock options or non-statutory stock options, as determined by the administrator at the time of grant of an option. RSUs and restricted stock may also be granted under the 2022 Plan. Grants vest in accordance with the grant terms. Options generally are exercisable for a period of up to 10 years from the grant date.

No options were granted in the three months and six months ended June 30, 2023.

Nocimed, Inc. 2015 Stock Plan

The Company maintains the Nocimed, Inc. 2015 Stock Plan, or the “Existing Plan”, under which the Company could grant 2,440,931 post-split shares or options of the Company to our employees, consultants, and other service providers. The Company suspended the Existing Plan in connection with the IPO. No further awards will be granted under the Existing Plan, but awards granted prior to the IPO will continue in accordance with their terms and the terms of the Existing Plan.

Determining Fair Value of Stock Options

The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

Valuation and Amortization Method —The Company estimates the fair value of its stock options using the Black-Scholes-Merton option-pricing model. This fair value is then amortized over the requisite service periods of the awards.

Expected Term—The Company estimates the expected term of stock option by taking the average of the vesting term and the contractual term of the option, as illustrated by the simplified method.

Expected Volatility—The expected volatility is derived from the Company’s expectations of future market volatility over the expected term of the options.

Risk-Free Interest Rate—The risk-free interest rate is based on the 10-year U.S. Treasury yield curve on the date of grant.

Dividend Yield—The dividend yield assumption is based on the Company’s history and expectation of no dividend payouts.

Stock Award Activity

A summary of option activity under the Company’s incentive plans is as follows:

	Options Outstanding		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)		Aggregate Intrinsic Value of Unexercised Options
Balance at December 31, 2022		2,738,820	$	1.94		8.4	$	0
Options granted		–		–		–
Options exercised		–		–		–
Options forfeited/expired		–		–		–
Balance at June 30, 2023		2,738,820	$	1.94		7.9	$	0
Exercisable at December 31, 2022		2,169,088	$	1.87		8.3	$	0
Exercisable at June 30, 2023		2,283,224	$	1.89		7.8	$	0

The aggregate intrinsic value in the table above of the unexercised options reflects the total pre-tax intrinsic value (the difference between the Nasdaq closing price on June 30, 2023, and the exercise price of the options that would have been received by option holders if all options exercisable had been exercised).

As of June 30, 2023, there was approximately $443,251 of total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over the next 27 months.

Restricted Stock Units

In the six months ended June 30, 2023, the Company granted RSUs under the 2022 Plan that have a combination of time-based and performance-based vesting, contingent upon continued service with the Company. The Company granted certain consultants an aggregate of 398,452 RSUs.

RSU activity under the 2022 Plan was as follows for the six months ended June 30, 2023: 

	RSU’s Outstanding			Weighted-Average Grant-Date Fair value per Unit
Nonvested as of December 31, 2022		446,525		$	0.63
Granted		398,452			0.76
Vested		(206,302	)		0.65
Forfeited		–			–
Nonvested as of June 30, 2023		638,675		$	0.70

The grant date fair value for a RSU is the market price of the common stock on the date of grant. The total share-based compensation expense related to RSUs recognized during the six months ended June 30, 2023, was $105,478.

As of June 30, 2023, there was approximately $281,330 total unrecognized compensation cost related to non-vested RSUs which is expected to be recognized over the next twelve months.

As of June 30, 2023, the Company is obligated to issue 241,692 shares of common stock associated with vested Restricted Stock Units.

Stock-based Compensation Expense

The following table summarizes the total stock-based compensation expense included in the Company’s statements of operations for the periods presented: 

	Three months ended June 30,				Six months ended June 30,
	2023		2022		2023		2022
Sales and marketing	$	78,688	$	848	$	106,997	$	1,696
Research and development		2,055		3,064		5,615		6,129
General and administrative		55,888		697,593		106,551		716,802
Total share based compensation	$	136,631	$	701,505	$	219,162	$	724,627

XML

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 15. SUBSEQUENT EVENTS

Resolution of Nasdaq Notice Regarding Late Filing of 10-Q Report

As previously disclosed, on May 23, 2023, the Company received a notice from Nasdaq notifying the Company that because the Company was delinquent in filing its Form 10-Q for the quarter ended March 31, 2023, the Company no longer complied with Nasdaq Listing Rule 5250(c)(1), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. On July 3, 2023, the Company filed its Form 10-Q for the quarter ended March 31, 2023 with the SEC. On July 5, 2023, the Company received a letter from Nasdaq indicating that the Company was now in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq’s letter indicated that this matter is now closed.

Nasdaq Non-Compliance

As indicated in our Form 12b-25 Notification of Late Filing filed on August 14, 2023, we have been delayed in filing with the SEC our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. On August 23, 2023, the Company received a notice from Nasdaq notifying the Company that because the Company remains delinquent in filing its Form 10-Q, the Company no longer complies with Nasdaq Listing Rule 5250(c)(1), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The notice received from Nasdaq has no immediate effect on the listing or trading of the Company’s securities on Nasdaq. However, if the Company would fail to timely regain compliance with Rule 5250(c)(1), the Company’s securities would be subject to delisting from Nasdaq. Under the Nasdaq rules, the Company has until October 22, 2023 (60 days after Nasdaq’s notice) to submit a plan to regain compliance with the Rule 5250(c)(1).  The Company expects that with the filing of this Form 10-Q, we have regained compliance with Rule 5250(c)(1).

Nasdaq Delisting Notices

On March 3, 2023, we received a letter from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. At December 31, 2022, we reported stockholders’ equity of $1,787,751 (prior to restatement, see Note 4 of form 10-K/A filed June 12, 2023), and, as a result, we did not satisfy Listing Rule 5550(b)(1). Nasdaq allowed us a period of 45 calendar days from the date of the letter, or until April 17, 2023, to submit a plan to regain compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). We submitted such a plan to Nasdaq on April 12, 2023. On April 20, 2023, the Company received a letter from Nasdaq granting us an additional 180-day period, or until August 30, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Separately, on August 4, 2023, we received a notice from Nasdaq indicating that we were not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). This notice indicated that the Company will be provided 180 calendar days in which to regain compliance. If at any time during this 180 calendar day period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq staff (the “Staff”) will provide the Company with a written confirmation of compliance and the matter will be closed.

Alternatively, if the Company fails to regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, the Company may be eligible for an additional 180 calendar day compliance period, provided (i) it meets the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the Bid Price Requirement) and (ii) it provides written notice to Nasdaq of its intention to cure this deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event the Company does not regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, and if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is not otherwise eligible, the Staff will provide the Company with written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Company intends to consider all options to regain compliance with all Nasdaq continued listing requirements.

Amendment to Unsecured Non-Convertible Notes

On May 16, 2023, the Company entered into a securities purchase agreement with accredited investors for an unsecured non-convertible note financing. The Company has received $1,250,000 of gross proceeds in connection with the first tranche closing of this financing.

Pursuant to the securities purchase agreement, the Company has the option, subject to certain conditions, to close on a second tranche of this financing. If the second tranche is closed, the Company would receive an additional $750,000 of gross proceeds in connection with the second tranche closing of this financing. The option for the second tranche is exercisable by the Company at any time until the earlier of (x) the date no first tranche notes remain outstanding and (y) the six-month anniversary of the first tranche closing date.

On August 14, 2023, the Company and the note holders agreed to waive monthly interest payments on the first tranche notes and the second tranche notes (if issued in the future).

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The financial statements include some amounts that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and valuation of warrants and options to purchase shares of the Company's common stock. These estimates may be adjusted as more current information becomes available, and any adjustment could be significant.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1 - Unadjusted quoted prices in active markets for identical instruments that are accessible by the Company on the measurement date.

Level 2 - Quoted prices in markets that are not active or inputs which are either directly or indirectly observable.

Level 3 - Unobservable inputs for the instrument requiring the development of assumptions by the Company.

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The carrying values of the Company’s financial instruments including cash equivalents, restricted cash, accounts receivable, and accounts payable are approximately equal to their respective fair values due to the relatively short-term nature of these instruments. The Company’s warrant liabilities and derivative liabilities are estimated using level 3 inputs (see Note 3).

Derivative Financial Instruments

Derivative Financial Instruments

The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expenses), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at June 30, 2023 and December 31, 2022. The Company maintains cash deposits at several financial institutions, which are insured by the FDIC up to $250,000. The Company’s cash balance may at times exceed these limits. On June 30, 2023, and December 31, 2022, the Company had $81,088 and $1,229,863, respectively, in excess of federally insured limits. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company maintains no international bank accounts. As of June 30, 2023, the Company reported cash of $604,518 and restricted cash of $10,000 which aggregates to $614,518 and is reported on the statement of cash flows as cash and restricted cash.

Accounts Receivable, Less Allowance for Doubtful Accounts

Accounts Receivable, Less Allowance for Doubtful Accounts

The Company estimates an allowance for doubtful accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was $0 on June 30, 2023, and December 31, 2022.

Revenue Recognition

Revenue Recognition

Revenues are recognized when a contract with a customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report, the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees. To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the billing schedules in its sales arrangements. Payment terms range generally from prepayment to 90 days from the date of invoice.

Liquidity, Capital Resources and Going Concern

Liquidity, Capital Resources and Going Concern

The Company had a cash and restricted cash balance of $614,518 as of June 30, 2023. On May 16, 2023, we entered into a securities purchase agreement with accredited investors for unsecured non-convertible note financing. The Company received $1,250,000 of gross proceeds in connection with the first tranche closing of this financing. The Company has the option, subject to certain conditions, to close on a second tranche of this financing. If the second tranche is closed, the Company will receive an additional $750,000 of gross proceeds. This interim bridge funding should allow the Company to operate into the third quarter of 2023. Management is actively managing our cash position and working to secure longer-term funding.

As a result of the Company’s recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.

Share-Based Compensation

Share-Based Compensation

The Company issues stock-based compensation awards to employees and directors in the form of stock options. The Company measures and recognizes compensation expense for all stock-based awards based on the awards’ fair value. Share-based compensation for stock options awards is measured on the date of grant using a Black-Scholes-Merton option pricing model.

Awards vest either on a graded schedule or at the grant date. The Company determines the fair value of each award as a single award and recognizes the expense on a straight-line basis over the service period of the award, which is generally the vesting period. The exercise price of stock options granted is equal to the fair market value of the Company’s common stock on the date of grant. Stock options expire ten years from the date of grant.

Emerging Growth Company Status

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period to comply with certain new or revised accounting standards that have different effective dates for public and private companies.

XML

FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Jun. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of recurring basis to determine the fair value of the liability

	Fair value measured as of June 30, 2023
	Fair value on June 30, 2023		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Warrant liability	$	582,399	$	–	$	–	$	582,399
Derivative Liability		172,389		–		–		172,389
Total Fair value	$	754,788	$	–	$	–	$	754,788

Schedule of liabilities measures at fair value

	Warrant Liability		Derivative Liability		Total
Balance - January 1, 2023	$	–	$	–	$	–
Additional warrant and derivative liability		579,818		163,170		742,988
Change in fair value		2,581		9,219		11,800
Balance - June 30, 2023	$	582,399	$	172,389	$	754,788

Schedule of assumptions

	As of Issuance		As of June 30, 2023
	Warrant Liability		Warrant Liability
Strike Price	$	0.63	$	0.63
Contractual term (years)		5.0		5.0
Volatility (annual)		80.0%		80.0%
Risk-free rate		3.52%		4.15%
Floor Financing price	$	0.50	$	0.50

XML

CORRECTION OF ERRORS IN 2022 INTERIM FINANCIAL INFORMATION (Tables)

6 Months Ended

Jun. 30, 2023

Accounting Changes and Error Corrections [Abstract]

SCHEDULE OF ERROR CORRECTIONS

Condensed Balance Sheets	For the six months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Total assets	$	5,620,989		$	–		$	5,620,989
Total current liabilities		1,381,419			–			1,381,419
Additional paid-in capital		41,184,654			(152,653	)		41,032,001
Accumulated deficit		(36,945,162	)		152,653			(36,792,509	)
Other		78			–			78
Total stockholders’ equity		4,239,570			–			4,239,570
Total liabilities and stockholders’ equity	$	5,620,989		$	–		$	5,620,989

Condensed Statements of Operations	For the six months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Gross profit (loss)	$	(11,279	)	$	–		$	(11,279	)
Sales and marketing		194,067			–			194,067
Research and development		558,029			–			558,029
General and administrative		2,375,126			(152,653	)		2,222,473
Total operating expenses		3,127,222			(152,653	)		2,974,569
Total other income (expense)		(1,505,102	)		–			(1,505,102	)
Net income (loss)	$	(4,643,603	)	$	152,653		$	(4,490,950	)
Net (loss) allocable to common stockholders	$	(5,059,126	)	$	152,653		$	(4,906,473	)
(Loss) per share	$	(1.16	)	$	0.04		$	(1.12	)
Weighted Average common shares outstanding		4,363,600			10,068			4,373,668

Condensed Statements of Operations	For the three months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Gross profit (loss)	$	(3,573	)	$	–		$	(3,573	)
Sales and marketing		124,759			–			124,759
Research and development		353,226			–			353,226
General and administrative		1,883,843			(152,653	)		1,731,190
Total operating expenses		2,361,828			(152,653	)		2,209,175
Total other income (expense)		(1,342,114	)		–			(1,342,114	)
Net income (loss)	$	(3,707,515	)	$	152,653		$	(3,554,862	)
Net (loss) allocable to common stockholders	$	(3,835,723	)	$	152,653		$	(3,683,070	)
(Loss) per share	$	(0.49	)	$	0.02		$	(0.47	)
Weighted Average common shares outstanding		7,821,515			–			7,821,515

Condensed Statements of Cash Flows	For the six months ended June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Net income (loss)	$	(4,643,603	)	$	152,653		$	(4,490,950	)
Adjustments to reconcile net income (loss) to net cash used in operation activities
Depreciation and amortization		94,705			(25,000	)		69,705
Non-cash charge settled in equity		–			1,299,507			1,299,507
Prepaids and other current assets		(308,052	)		(140,382	)		(448,434	)
Accrued and other liabilities		728,399			(921,718	)		(193,320	)
Other		1,047,540			–			1,047,540
Net cash (used in) operations		(3,081,011	)		365,060			(2,715,951	)
Net cash (used in) investing activities		(120,957	)		–			(120,957	)
IPO Issuance costs		–			(365,060	)		(365,060	)
Others		6,552,318			–			6,552,318
Net cash provided by financing activities		6,552,318			(365,060	)		6,187,258
Net cash increase (decrease) for period	$	3,350,350		$	–		$	3,350,350

Condensed Statements of Changes in Stockholders’ Equity	June 30, 2022 (unaudited)
	As previously reported			Adjustments			As Restated
Common Stock	$	78		$	–		$	78
Additional paid-in capital		41,184,654			(152,653	)		41,032,001
Accumulated deficit		(36,945,162	)		152,653			(36,792,509	)
Total stockholders’ equity	$	4,239,570		$	–		$	4,239,570

XML

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)

6 Months Ended

Jun. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of accrued and other liabilities

	June 30, 2023		December 31, 2022
Accrued bonus	$	291,812	$	134,704
Accrued expenses		153,805		35,922
Accrued payroll and related liabilities		47,023		46,250
Accrued interest		14,346		–
Other accrued liabilities		6,014		9,593
	$	513,000	$	226,469

XML

INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

	June 30, 2023			December 31, 2022
Patents and licenses	$	2,220,363		$	2,147,728
Other		5,017			5,017
		2,225,380			2,152,745
Less: accumulated amortization		(1,021,343	)		(942,538	)
Intangible assets, net	$	1,204,037		$	1,210,207

Schedule of future amortization

2023	$	81,096
2024		162,191
2025		162,191
2026		162,191
2027 and beyond		636,368
Total	$	1,204,037

XML

SHORT TERM NOTES, CONVERTIBLE DEBT, AND DERIVATIVE LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

Schedule of derivative liabilities

	June 30, 2023			December 31, 2022
Note Payable	$	1,437,500		$	–
Less: Unamortized Discounts and Deferred Financing Costs					–
Warrants		(567,543	)		–
Derivative		(159,716	)		–
Issuance cost		(591,403	)		–
		(1,318,662	)		–
	$	118,838		$	–

XML

NET LOSS PER SHARE OF COMMON STOCK (Tables)

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

Reconciliation of diluted shares

	Three Months Ended June 30,
	2023			2022
Numerator:
Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share	$	(1,464,557	)	$	(3,683,070	)
Denominator:
Weighted average shares outstanding used to compute basic and dilutive loss per share		8,087,755			–
Weighted average shares issuable for vested restricted stock units		199,914			–
		8,287,669			7,821,515

	Six Months Ended June 30,
	2023			2022
Numerator:
Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share	$	(2,648,017	)	$	(4,906,473	)
Denominator:
Weighted average shares outstanding used to compute basic and dilutive loss per share		7,974,635			4,373,668
Weighted average shares issuable for vested restricted stock units		145,347			–
		8,119,982			4,373,668

Schedule of anti-dilutive securities excluded from computation of earnings per share

	June 30, 2023		June 30, 2022
Series A and B convertible preferred stock		–		1,639,559
Warrants		3,518,550		1,570,236
Restricted stock units		692,422		–
Stock options		2,738,820		2,351,510
		6,949,792		5,561,305

XML

STOCK BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of option activity

	Options Outstanding		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)		Aggregate Intrinsic Value of Unexercised Options
Balance at December 31, 2022		2,738,820	$	1.94		8.4	$	0
Options granted		–		–		–
Options exercised		–		–		–
Options forfeited/expired		–		–		–
Balance at June 30, 2023		2,738,820	$	1.94		7.9	$	0
Exercisable at December 31, 2022		2,169,088	$	1.87		8.3	$	0
Exercisable at June 30, 2023		2,283,224	$	1.89		7.8	$	0

Schedule of RSU activity

	RSU’s Outstanding			Weighted-Average Grant-Date Fair value per Unit
Nonvested as of December 31, 2022		446,525		$	0.63
Granted		398,452			0.76
Vested		(206,302	)		0.65
Forfeited		–			–
Nonvested as of June 30, 2023		638,675		$	0.70

Schedule of stock-based compensation expense

	Three months ended June 30,				Six months ended June 30,
	2023		2022		2023		2022
Sales and marketing	$	78,688	$	848	$	106,997	$	1,696
Research and development		2,055		3,064		5,615		6,129
General and administrative		55,888		697,593		106,551		716,802
Total share based compensation	$	136,631	$	701,505	$	219,162	$	724,627

XML

THE COMPANY AND BASIS OF PRESENTATION (Details Narrative) - USD ($)		1 Months Ended
	Apr. 26, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reported stockholders equity		$ 1,787,751
Unit Of Common Stock And Warrant [Member] | IPO [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues	2,165,000
Proceeds from Issuance or Sale of Equity	$ 8,600,000
Common Stock Warrants [Member] | IPO [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares converted	426,768
Common Stock Warrants [Member] | IPO [Member] | Underwriters [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues	324,750
Common Stock [Member] | IPO [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares converted	4,750,830
Warrants [Member] | IPO [Member] | Underwriters [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Underwriters a common stock warrant	173,200
Stock warrant exercise price	$ 5.44
Warrants and Rights Outstanding, Maturity Date	Apr. 26, 2027

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash Equivalents, at Carrying Value	$ 0	$ 0
Cash, Uninsured Amount	81,088	1,229,863
Restricted Cash	10,000	10,000
Accounts Receivable, Allowance for Credit Loss	0	$ 0
Restricted Cash and Cash Equivalents	$ 614,518

XML

FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)	Jun. 30, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	$ 754,788
Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	754,788
Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	582,399
Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	0
Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	0
Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	582,399
Derivative Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	172,389
Derivative Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	0
Derivative Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	0
Derivative Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value liability	$ 172,389

XML

FAIR VALUE MEASUREMENTS (Details - liabilities measures at fair value)	6 Months Ended
	Jun. 30, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance - January 1, 2023	$ 0
Additional warrant and derivative liability	742,988
Change in fair value	11,800
Balance - June 30, 2023	754,788
Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance - January 1, 2023	0
Additional warrant and derivative liability	579,818
Change in fair value	2,581
Balance - June 30, 2023	582,399
Derivative Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance - January 1, 2023	0
Additional warrant and derivative liability	163,170
Change in fair value	9,219
Balance - June 30, 2023	$ 172,389

XML

FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)	6 Months Ended
	Jun. 30, 2023 $ / shares
Issuance Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Strike Price	$ 0.63
Contractual term	5 years
Volatility	80.00%
Risk-free rate	3.52%
Floor Financing price	$ 0.50
Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Strike Price	$ 0.63
Contractual term	5 years
Volatility	80.00%
Risk-free rate	4.15%
Floor Financing price	$ 0.50

XML

SCHEDULE OF ERROR CORRECTIONS (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total assets	$ 2,004,466		$ 5,620,989		$ 2,004,466	$ 5,620,989	$ 2,914,629
Total current liabilities	1,994,242		1,381,419		1,994,242	1,381,419	688,671
Additional paid-in capital	42,028,310		41,032,001		42,028,310	41,032,001	41,596,032
Accumulated deficit	(42,018,169)		(36,792,509)		(42,018,169)	(36,792,509)	(39,370,153)
Other			78			78
Total stockholders’ equity	10,223	$ 1,125,029	4,239,570	$ (14,031,887)	10,223	4,239,570	2,225,958	$ (12,831,606)
Total liabilities and stockholders’ equity	2,004,466		5,620,989		2,004,466	5,620,989	2,914,629
Gross profit (loss)			(3,573)			(11,279)
Sales and marketing			124,759			194,067
Research and development	250,006		353,226		454,405	558,029
General and administrative	946,175		1,731,190		1,753,774	2,222,473
Total operating expenses	1,403,971		2,209,175		2,593,253	2,974,569
Total other income (expense)	(58,356)		(1,342,114)		(60,552)	(1,505,102)
Net income (loss)	(1,464,557)	$ (1,183,460)	(3,554,862)	$ (936,088)	(2,648,017)	(4,490,950)
Net (loss) allocable to common stockholders	$ (1,464,557)		$ (3,683,070)		$ (2,648,017)	$ (4,906,473)
Earnings Per Share, Basic	$ (0.18)		$ (0.47)		$ (0.33)	$ (1.12)
Earnings Per Share, Diluted	$ (0.18)		$ (0.47)		$ (0.33)	$ (1.12)
Weighted Average Number of Shares Outstanding, Basic	8,287,669		7,821,515		8,119,982	4,373,668
Weighted Average Number of Shares Outstanding, Diluted	8,287,669		7,821,515		8,119,982	4,373,668
Depreciation and amortization					$ 79,809	$ 69,705
Non-cash charge settled in equity						1,299,507
Prepaids and other current assets					33,287	(448,434)
Accrued and other liabilities						(193,320)
Other						1,047,540
Net cash (used in) operations					(1,960,653)	(2,715,951)
Net cash (used in) investing activities					(72,634)	(120,957)
IPO Issuance costs					(85,000)	(365,060)
Others						6,552,318
Net cash provided by financing activities					1,165,000	6,187,258
Net cash increase (decrease) for period					(868,287)	3,350,350
Common Stock	$ 82		$ 78		$ 82	78	$ 79
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total assets			5,620,989			5,620,989
Total current liabilities			1,381,419			1,381,419
Additional paid-in capital			41,184,654			41,184,654
Accumulated deficit			(36,945,162)			(36,945,162)
Other			78			78
Total stockholders’ equity			4,239,570			4,239,570
Total liabilities and stockholders’ equity			5,620,989			5,620,989
Gross profit (loss)			(3,573)			(11,279)
Sales and marketing			124,759			194,067
Research and development			353,226			558,029
General and administrative			1,883,843			2,375,126
Total operating expenses			2,361,828			3,127,222
Total other income (expense)			(1,342,114)			(1,505,102)
Net income (loss)			(3,707,515)			(4,643,603)
Net (loss) allocable to common stockholders			$ (3,835,723)			$ (5,059,126)
Earnings Per Share, Basic			$ (0.49)			$ (1.16)
Earnings Per Share, Diluted			$ (0.49)			$ (1.16)
Weighted Average Number of Shares Outstanding, Basic			7,821,515			4,363,600
Weighted Average Number of Shares Outstanding, Diluted			7,821,515			4,363,600
Depreciation and amortization						$ 94,705
Non-cash charge settled in equity						0
Prepaids and other current assets						(308,052)
Accrued and other liabilities						728,399
Other						1,047,540
Net cash (used in) operations						(3,081,011)
Net cash (used in) investing activities						(120,957)
IPO Issuance costs						0
Others						6,552,318
Net cash provided by financing activities						6,552,318
Net cash increase (decrease) for period						3,350,350
Common Stock			$ 78			78
Revision of Prior Period, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total assets
Total current liabilities			0			0
Additional paid-in capital			(152,653)			(152,653)
Accumulated deficit			152,653			152,653
Other			0			0
Total stockholders’ equity			0			0
Total liabilities and stockholders’ equity			0			0
Gross profit (loss)						0
Sales and marketing			0			0
Research and development			0			0
General and administrative			(152,653)			(152,653)
Total operating expenses			(152,653)			(152,653)
Total other income (expense)			0			0
Net income (loss)			152,653			152,653
Net (loss) allocable to common stockholders			$ 152,653			$ 152,653
Earnings Per Share, Basic			$ 0.02			$ 0.04
Earnings Per Share, Diluted			$ 0.02			$ 0.04
Weighted Average Number of Shares Outstanding, Basic			0			10,068
Weighted Average Number of Shares Outstanding, Diluted			0			10,068
Depreciation and amortization						$ (25,000)
Non-cash charge settled in equity						1,299,507
Prepaids and other current assets						(140,382)
Accrued and other liabilities						(921,718)
Other						0
Net cash (used in) operations						365,060
Net cash (used in) investing activities						0
IPO Issuance costs						(365,060)
Others						0
Net cash provided by financing activities						(365,060)
Net cash increase (decrease) for period						0
Common Stock			$ 0			$ 0

XML

SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued bonus	$ 291,812	$ 134,704
Accrued expenses	153,805	35,922
Accrued payroll and related liabilities	47,023	46,250
Accrued interest	14,346	0
Other accrued liabilities	6,014	9,593
Accrued and other liabilities	$ 513,000	$ 226,469

XML

LEASES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases
Operating Lease, Expense	$ 0	$ 16,425	$ 0	$ 32,510
Operating Leases, Income Statement, Sublease Revenue			$ 0	$ 26,340

XML

INTANGIBLE ASSETS (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Total intangible assets gross	$ 2,225,380	$ 2,152,745
Less: accumulated amortization	(1,021,343)	(942,538)
Intangible assets, net	1,204,037	1,210,207
Patents And Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets gross	2,220,363	2,147,728
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets gross	$ 5,017	$ 5,017

XML

INTANGIBLE ASSETS (Details - future amortization)	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 81,096
2024	162,191
2025	162,191
2026	162,191
2027 and beyond	636,368
Total	$ 1,204,037

XML

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 39,940	$ 33,396	$ 78,805	$ 66,583
Impairment of Intangible Assets, Finite-Lived			$ 0		$ 0

XML

SUPPLEMENTAL FINANCIAL INFORMATION (Details - Note payable) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Note Payable	$ 1,437,500	$ 0
Warrants	(567,543)	0
Derivative	(159,716)	0
Issuance cost	(591,403)	0
Total notes payable discount	(1,318,662)	0
Note payable, net of discount	$ 118,838	$ 0

XML

SHORT TERM NOTES, CONVERTIBLE DEBT, AND DERIVATIVE LIABILITIES (Details Narrative) - USD ($)				3 Months Ended	6 Months Ended
	May 31, 2023	Apr. 27, 2022	Apr. 21, 2022	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Fair value of warrants					$ 742,988
Stock issued new, value				$ 175,619
Notes Payable				1,437,500	1,437,500		$ 0
Repayments of Notes Payable					$ (0)	$ 2,000,000
Interest Converted To Common Stock [Member]
Debt Instrument [Line Items]
Beneficial conversion expense			$ 1,299,507
Interest Converted To Common Stock [Member] | Post Split Shares [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Debt converted, shares issued			426,768
Interest Converted To Common Stock [Member] | Post Split Shares [Member] | Warrant [Member]
Debt Instrument [Line Items]
Debt converted, shares issued			426,768
Qualified Financing [Member]
Debt Instrument [Line Items]
Notes Payable								$ 2,000,000
Repayments of Notes Payable		$ 2,000,000
Senior Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 1,437,500
Proceeds from Secured Notes Payable	1,250,000
Debt Issuance Costs, Gross	203,575
Debt Instrument, Unamortized Discount	$ 163,170
Amortization of debt discount				$ 28,520
Senior Notes Payable [Member] | Commitment Fee [Member]
Debt Instrument [Line Items]
Stock issued new, shares	339,360
Stock issued new, value	$ 175,619
Senior Notes Payable [Member] | Senior Notes Warrants [Member]
Debt Instrument [Line Items]
Warrants issued	1,232,156
Fair value of warrants	$ 579,818

XML

COMMITMENTS AND CONTINGENCIES (Details Narrative) - Regents Of The University Of California [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum annual royalty payment	$ 50,000		$ 50,000
Royalty Expense	$ 12,500	$ 12,500	$ 25,000	$ 25,000

XML

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)				1 Months Ended	6 Months Ended	12 Months Ended
	Mar. 24, 2023	Apr. 26, 2022	Apr. 22, 2022	Feb. 28, 2023	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common Stock, Shares Authorized					200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share					$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized					20,000,000
Preferred Stock, Par or Stated Value Per Share					$ 0.00001
Common stock, shares outstanding					8,200,875	7,861,515
Redemption price					$ 1,000
Class of Warrant or Right, Outstanding					2,489,750
Unit Of Common Stock And Warrant [Member] | IPO [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		2,165,000
IPO Warrants [Member] | IPO [Member] | Underwriters [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			324,750
Warrants [Member] | IPO [Member] | Underwriters [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		173,200
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.44
Warrants and Rights Outstanding, Maturity Date		Apr. 26, 2027
Warrants Converted To Common Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Issued					60,408
Warrants Issued For Convertible Notes [Member]
Class of Stock [Line Items]
Warrants issued shares						17,286	58,846
Pre Funded Placement Agent Warrants [Member]
Class of Stock [Line Items]
Number of shares issued					$ 54,340
Executive Chairman [Member]
Class of Stock [Line Items]
Purchase price				$ 1,000
Minimum [Member]
Class of Stock [Line Items]
Stockholders Equity, Reverse Stock Split	one-for-five (1-for-5)
Maximum [Member]
Class of Stock [Line Items]
Stockholders Equity, Reverse Stock Split	one-for-fifty (1-for-50) split

XML

NET LOSS PER SHARE OF COMMON STOCK (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share	$ (1,464,557)	$ (3,683,070)	$ (2,648,017)	$ (4,906,473)
Weighted average shares outstanding used to compute basic and dilutive loss per share	8,087,755	0	7,974,635	4,373,668
Weighted average shares issuable for vested restricted stock units	199,914	0	145,347	0
Total weighted average shares diluted	8,287,669	7,821,515	8,119,982	4,373,668

XML

NET LOSS PER SHARE OF COMMON STOCK (Details - dilutive securities) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	6,949,792	5,561,305
Series A And B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	0	1,639,559
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	3,518,550	1,570,236
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	692,422	0
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	2,738,820	2,351,510

XML

STOCK BASED COMPENSATION (Details - Option Activity) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Options oustanding, beginning balance		2,738,820
Weighted average exercise price, beginning balance		$ 1.94
Weighted average remaining contractual life		7 years 10 months 24 days	8 years 4 months 24 days
Aggregate intrinsic value of unexercised options, beginning balance		$ 0
Options oustanding, granted	0	0
Weighted average exercise price, granted		$ 0
Options oustanding, exercised		$ 0
Weighted average exercise price, exercised		$ 0
Options oustanding, forfeited/expired		0
Weighted average exercise price, forfeited/expired		$ 0
Options oustanding, ending balance	2,738,820	2,738,820	2,738,820
Weighted average exercise price, ending balance	$ 1.94	$ 1.94	$ 1.94
Aggregate intrinsic value of unexercised options, ending balance	$ 0	$ 0	$ 0
Options oustanding, exercisable	2,283,224	2,283,224	2,169,088
Weighted average exercise price, exercisable	$ 1.89	$ 1.89	$ 1.87
Weighted average remaining contractual life, exercisable			8 years 3 months 18 days
Aggregate intrinsic value of unexercised options, exercisable	$ 0	$ 0	$ 0
Weighted average remaining contractual life, exercisable		7 years 9 months 18 days

XML

STOCK BASED COMPENSATION (Details - RSU Activity) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
RSU nonvested outstanding, beginning balance | shares	446,525
Weighted average grant date fair value per unit nonvested, beginning balance | $ / shares	$ 0.63
RSU nonvested outstanding, granted | shares	398,452
Weighted average grant date fair value per unit nonvested, granted | $ / shares	$ 0.76
RSU nonvested outstanding, vested | shares	(206,302)
Weighted average grant date fair value per unit nonvested, vested | $ / shares	$ 0.65
RSU nonvested outstanding, forfeited | shares	0
Weighted average grant date fair value per unit nonvested, forfeited | $ / shares	$ 0
RSU nonvested outstanding, ending balance | shares	638,675
Weighted average grant date fair value per unit nonvested, ending balance | $ / shares	$ 0.70

XML

STOCK BASED COMPENSATION (Details - Share based compensation) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation	$ 136,631	$ 701,505	$ 219,162	$ 724,627
Selling and Marketing Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation	78,688	848	106,997	1,696
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation	2,055	3,064	5,615	6,129
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation	$ 55,888	$ 697,593	$ 106,551	$ 716,802

XML

STOCK BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Apr. 21, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options granted	0	0
Unrecognized compensation cost	$ 443,251	$ 443,251
Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost, remaining term		27 months
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense		$ 105,478
Unrecognized compensation cost	$ 281,330	$ 281,330
Aclarion Equity Incentive Plan 2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Authorized	2,393,076	2,393,076	2,000,000